Deoxyuridine    B-Pyrimidine114999913
(    O
dU    B-Pyrimidine114999913
)    O
is    O
a    O
compound    O
and    O
a    O
nucleoside    O
.    O

Deoxyuridine    B-Pyrimidine114999913

prazitone    B-Pyrimidine114999913
(    O
INN    O
)    O

Alphenal    B-Pyrimidine114999913
(    O
Alphenal    B-Pyrimidine114999913
,    O
Efrodal    B-Pyrimidine114999913
,    O
Prophenal    B-Pyrimidine114999913
,    O
Sanudorm    B-Pyrimidine114999913
)    O
,    O
also    O
known    O
as    O
5-allyl-5-phenylbarbituric    B-Pyrimidine114999913
acid    I-Pyrimidine114999913
,    O
is    O
a    O
barbiturate    O
derivative    O
developed    O
in    O
the    O
1920s    O
.    O

Reposal    B-Pyrimidine114999913
is    O
a    O
barbiturate    O
derivative    O
invented    O
in    O
the    O
1960s    O
in    O
Denmark    O
.    O

Tandospirone    B-Pyrimidine114999913
-    O
anxiolytic    O

It    O
is    O
an    O
antagonist    O
at    O
most    O
or    O
all    O
of    O
the    O
receptors    O
it    O
binds    O
to    O
except    O
the    O
5-HT1A    O
receptor    O
,    O
where    O
it    O
acts    O
as    O
a    O
partial    O
agonist    O
similarly    O
to    O
buspirone    O
and    O
tandospirone    B-Pyrimidine114999913
but    O
with    O
comparatively    O
greater    O
intrinsic    O
activity    O
.    O

Darusentan    B-Pyrimidine114999913
(    O
LU-135252    O
;    O
HMR-4005    O
)    O
is    O
an    O
endothelin    O
receptor    O
antagonist    O
.    O

BHF-177    B-Pyrimidine114999913
is    O
a    O
compound    O
used    O
in    O
scientific    O
research    O
which    O
acts    O
as    O
a    O
positive    O
allosteric    O
modulator    O
at    O
the    O
GABAB    O
receptor    O
.    O

glymidine    B-Pyrimidine114999913
sodium    I-Pyrimidine114999913
(    O
INN    O
)    O

The    O
first    O
anticodon    O
base    O
,    O
or    O
wobble    O
-    O
position    O
,    O
is    O
sometimes    O
modified    O
to    O
inosine    O
(    O
derived    O
from    O
adenine    O
)    O
,    O
pseudouridine    B-Pyrimidine114999913
or    O
lysidine    B-Pyrimidine114999913
(    O
derived    O
from    O
cytosine    O
)    O
.    O

TC-1827    B-Pyrimidine114999913

Cytidine    B-Pyrimidine114999913
diphosphate    I-Pyrimidine114999913
,    O
abbreviated    O
CDP    B-Pyrimidine114999913
,    O
is    O
a    O
nucleoside    O
diphosphate    O
.    O

They    O
are    O
synthesized    O
by    O
the    O
addition    O
of    O
cytidine    B-Pyrimidine114999913
diphosphate    I-Pyrimidine114999913
-    O
ethanolamine    O
to    O
diglycerides    O
,    O
releasing    O
cytidine    B-Pyrimidine114999913
monophosphate    I-Pyrimidine114999913
.    O

gemcitabine    B-Pyrimidine114999913
(    O
INN    O
)    O

Gemzar    B-Pyrimidine114999913
(    O
Eli    O
Lilly    O
)    O

On    O
the    O
other    O
hand    O
,    O
adding    O
infliximab    O
or    O
etanercept    O
to    O
gemcitabine    B-Pyrimidine114999913
for    O
treating    O
patients    O
with    O
advanced    O
pancreatic    O
cancer    O
was    O
not    O
associated    O
with    O
differences    O
in    O
efficacy    O
when    O
compared    O
with    O
placebo    O
.    O

After    O
surgery    O
,    O
adjuvant    O
chemotherapy    O
with    O
gemcitabine    B-Pyrimidine114999913
or    O
5-FU    O
can    O
be    O
offered    O
if    O
the    O
person    O
is    O
sufficiently    O
fit    O
,    O
after    O
a    O
recovery    O
period    O
of    O
one    O
to    O
two    O
months    O
.    O

He    O
is    O
the    O
principal    O
investigator    O
for    O
a    O
clinical    O
trial    O
of    O
neoadjuvant    O
gemcitabine    B-Pyrimidine114999913
and    O
cisplatin    O
followed    O
by    O
extrapleural    O
pneumonectomy    O
and    O
high    O
-    O
dose    O
radiation    O
.    O

Pharmaceuticals    O
,    O
including    O
the    O
chemotherapy    O
medication    O
gemcitabine    B-Pyrimidine114999913
,    O
as    O
well    O
as    O
certain    O
interleukins    O
and    O
monoclonal    O
antibodies    O
,    O
can    O
also    O
cause    O
capillary    O
leaks    O
.    O

In    O
a    O
preclinical    O
mouse    O
model    O
of    O
pancreatic    O
cancer    O
,    O
it    O
was    O
"    O
even    O
more    O
effective    O
than    O
gemcitabine    B-Pyrimidine114999913
"    O
.    O

Systemic    O
chemotherapies    O
such    O
as    O
gemcitabine    B-Pyrimidine114999913
and    O
cisplatin    O
are    O
sometimes    O
used    O
in    O
inoperable    O
cases    O
of    O
cholangiocarcinoma    O
.    O

:    O
J01ED03    O
Sulfametomidine    B-Pyrimidine114999913

Vicriviroc    B-Pyrimidine114999913
,    O
similar    O
to    O
maraviroc    O
,    O
is    O
currently    O
undergoing    O
clinical    O
trials    O
for    O
FDA    O
approval    O
.    O

:    O
N05CA09    O
Vinbarbital    B-Pyrimidine114999913

Lorediplon    B-Pyrimidine114999913
(    O
INN    O
)    O
is    O
a    O
nonbenzodiazepine    O
of    O
the    O
pyrazolopyrimidine    O
family    O
that    O
is    O
being    O
pursued    O
as    O
a    O
treatment    O
for    O
insomnia    O
but    O
has    O
not    O
completed    O
development    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dCTP    B-Pyrimidine114999913
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
dCMP    O
and    O
diphosphate    O
.    O

Twenty    O
different    O
pesticides    O
were    O
detected    O
in    O
on    O
-    O
site    O
soil    O
surface    O
samples    O
including    O
diazinon    B-Pyrimidine114999913
,    O
endosulfan    O
and    O
heptachlor    O
epoxide    O
,    O
which    O
were    O
found    O
at    O
highest    O
levels    O
in    O
the    O
burn    O
area    O
,    O
and    O
disulfoton    O
,    O
endosulfan    O
,    O
merphos    O
,    O
and    O
methamidophos    O
which    O
were    O
found    O
in    O
high    O
concentrations    O
near    O
the    O
former    O
warehouse    O
and    O
office    O
.    O

Mealybugs    O
also    O
infest    O
some    O
species    O
of    O
carnivorous    O
plant    O
such    O
as    O
"    O
Sarracenia    O
"    O
(    O
pitcher    O
plants    O
)    O
;    O
in    O
such    O
cases    O
it    O
is    O
difficult    O
to    O
eradicate    O
them    O
without    O
repeated    O
applications    O
of    O
insecticide    O
such    O
as    O
diazinon    B-Pyrimidine114999913
.    O

Diazinon    B-Pyrimidine114999913
can    O
be    O
used    O
,    O
but    O
often    O
requires    O
multiple    O
applications    O
.    O

Brands    O
included    O
in    O
United    O
Industries    O
were    O
Vigoro    O
,    O
Spectracide    B-Pyrimidine114999913
and    O
Sta    O
-    O
Green    O
lawn    O
products    O
,    O
Cutter    O
,    O
Hot    O
Shot    O
and    O
Repel    O
insect    O
control    O
products    O
and    O
pet    O
supply    O
products    O
with    O
the    O
Marineland    O
,    O
Perfecto    O
,    O
and    O
Eight    O
in    O
One    O
brands    O
.    O

Stavudine    B-Pyrimidine114999913
,    O
also    O
called    O
d4    O
T    O
,    O
has    O
trade    O
names    O
Zerit    O
and    O
Zerit    O
XR    O
.    O

Thymidine    O
analogues    O
:    O
zidovudine    O
(    O
AZT    O
)    O
and    O
stavudine    B-Pyrimidine114999913
(    O
d4    O
T    O
)    O

Administration    O
with    O
drugs    O
with    O
overlapping    O
toxicity    O
,    O
such    O
as    O
zalcitabine    O
and    O
stavudine    B-Pyrimidine114999913
,    O
is    O
not    O
recommended    O
.    O

Additionally    O
,    O
zalcitabine    O
should    O
not    O
be    O
used    O
with    O
other    O
drugs    O
that    O
can    O
cause    O
peripheral    O
neuropathy    O
,    O
such    O
as    O
didanosine    O
and    O
stavudine    B-Pyrimidine114999913
.    O

Stavudine    B-Pyrimidine114999913
(    O
d4T    B-Pyrimidine114999913
)    O
,    O
sold    O
under    O
the    O
brand    O
name    O
Zerit    B-Pyrimidine114999913
among    O
others    O
,    O
is    O
an    O
antiretroviral    O
medication    O
used    O
to    O
prevent    O
and    O
treat    O
HIV    O
/    O
AIDS    O
.    O

While    O
trying    O
to    O
isolate    O
the    O
bacterial    O
toxin    O
responsible    O
for    O
tuberculosis    O
,    O
W.G.    O
Ruppel    O
isolated    O
a    O
novel    O
nucleic    O
acid    O
named    O
tuberculinic    B-Pyrimidine114999913
acid    I-Pyrimidine114999913
in    O
1898    O
from    O
"    O
Tubercle    O
bacillus    O
"    O
.    O

UBP-302    B-Pyrimidine114999913

Endothelin-1    O
receptor    O
antagonists    O
(    O
Bosentan    B-Pyrimidine114999913
)    O
are    O
used    O
in    O
the    O
treatment    O
of    O
pulmonary    O
hypertension    O
.    O

A    O
number    O
of    O
treatments    O
have    O
been    O
investigated    O
in    O
the    O
past    O
for    O
IPF    O
,    O
including    O
interferon    O
gamma-1β    O
,    O
bosentan    B-Pyrimidine114999913
,    O
ambrisentan    B-Pyrimidine114999913
,    O
and    O
anticoagulants    O
,    O
but    O
these    O
are    O
no    O
longer    O
considered    O
effective    O
treatment    O
options    O
.    O

The    O
rationale    O
for    O
benefit    O
compared    O
with    O
bosentan    B-Pyrimidine114999913
,    O
a    O
nonselective    O
ET    O
blocker    O
,    O
is    O
negligible    O
inhibition    O
of    O
the    O
beneficial    O
effects    O
of    O
ETB    O
stimulation    O
,    O
such    O
as    O
nitric    O
oxide    O
production    O
and    O
clearance    O
of    O
ET    O
from    O
circulation    O
.    O

dual    O
antagonists    O
(    O
bosentan    B-Pyrimidine114999913
,    O
macitentan    O
,    O
tezosentan    B-Pyrimidine114999913
)    O
,    O
which    O
affect    O
both    O
endothelin    O
A    O
and    O
B    O
receptors    O
.    O

TB10Cs1H1    O
is    O
predicted    O
to    O
guide    O
the    O
pseudouridylation    B-Pyrimidine114999913
of    O
LSU3    O
ribosomal    O
RNA    O
(    O
rRNA    O
)    O
at    O
residue    O
Ψ659    O
.    O

TB9Cs3H1    O
is    O
predicted    O
to    O
guide    O
the    O
pseudouridylation    B-Pyrimidine114999913
of    O
LSU3    O
ribosomal    O
RNA    O
(    O
rRNA    O
)    O
at    O
residue    O
Ψ1208    O
.    O

TB8Cs3H1    O
is    O
predicted    O
to    O
guide    O
the    O
pseudouridylation    B-Pyrimidine114999913
of    O
SSU    O
ribosomal    O
RNA    O
(    O
rRNA    O
)    O
at    O
residue    O
Ψ1423    O
.    O

TB9Cs2H1    O
is    O
predicted    O
to    O
guide    O
the    O
pseudouridylation    B-Pyrimidine114999913
of    O
LSU3    O
ribosomal    O
RNA    O
(    O
rRNA    O
)    O
at    O
residue    O
Ψ617    O
.    O

TB10Cs2H1    O
is    O
predicted    O
to    O
guide    O
the    O
pseudouridylation    B-Pyrimidine114999913
of    O
LSU3    O
ribosomal    O
RNA    O
(    O
rRNA    O
)    O
at    O
residue    O
Ψ1167    O
.    O

TB10Cs1H3    O
is    O
predicted    O
to    O
guide    O
the    O
pseudouridylation    B-Pyrimidine114999913
of    O
SSU    O
ribosomal    O
RNA    O
(    O
rRNA    O
)    O
at    O
residue    O
Ψ40    O
.    O

TB10Cs3H1    O
is    O
predicted    O
to    O
guide    O
the    O
pseudouridylation    B-Pyrimidine114999913
of    O
SSU    O
ribosomal    O
RNA    O
(    O
rRNA    O
)    O
at    O
residue    O
Ψ263    O
.    O

TB10Cs3H2    O
is    O
predicted    O
to    O
guide    O
the    O
pseudouridylation    B-Pyrimidine114999913
of    O
LSU3    O
ribosomal    O
RNA    O
(    O
rRNA    O
)    O
at    O
residue    O
Ψ397    O
.    O

TB11Cs4H2    O
is    O
predicted    O
to    O
guide    O
the    O
pseudouridylation    B-Pyrimidine114999913
of    O
SSU    O
ribosomal    O
RNA    O
(    O
rRNA    O
)    O
at    O
residue    O
Ψ1907    O
.    O

TB9Cs4H2    O
is    O
predicted    O
to    O
guide    O
the    O
pseudouridylation    B-Pyrimidine114999913
of    O
LSU3    O
ribosomal    O
RNA    O
(    O
rRNA    O
)    O
at    O
residue    O
Ψ1336    O
.    O

Pseudouridine    B-Pyrimidine114999913
(    O
abbreviated    O
by    O
the    O
Greek    O
letter    O

The    O
relevant    O
nature    O
of    O
dyskerin    O
throughout    O
most    O
species    O
is    O
to    O
catalyze    O
the    O
post    O
-    O
transcriptional    O
pseudouridylation    B-Pyrimidine114999913
of    O
specific    O
uridine    B-Pyrimidine114999913
found    O
in    O
non    O
-    O
coding    O
RNAs    O
,    O
such    O
as    O
ribosomal    O
RNA    O
(    O
rRNA    O
)    O
.    O

#    O
The    O
T    O
arm    O
is    O
a    O
4-    O
to    O
5-    O
bp    O
stem    O
containing    O
the    O
sequence    O
TΨC    O
where    O
Ψ    O
is    O
pseudouridine    B-Pyrimidine114999913
,    O
a    O
modified    O
uridine    B-Pyrimidine114999913
.    O

The    O
first    O
anticodon    O
base    O
,    O
or    O
wobble    O
-    O
position    O
,    O
is    O
sometimes    O
modified    O
to    O
inosine    O
(    O
derived    O
from    O
adenine    O
)    O
,    O
pseudouridine    B-Pyrimidine114999913
or    O
lysidine    B-Pyrimidine114999913
(    O
derived    O
from    O
cytosine    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
pseudouridine    B-Pyrimidine114999913
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
pseudouridine    O
5'-phosphate    O
.    O

Thus    O
,    O
while    O
pseudouridine    B-Pyrimidine114999913
and    O
2’-O    O
-    O
methylations    O
stabilize    O
the    O
local    O
RNA    O
structure    O
,    O
D    O
does    O
the    O
opposite    O
.    O

Thiamine    B-Pyrimidine114999913
monophosphate    I-Pyrimidine114999913
is    O
a    O
thiamine    O
derivative    O
.    O

Although    O
all    O
strains    O
of    O
"    O
M.    O
catarrhalis    O
"    O
were    O
susceptible    O
to    O
cotrimoxazole    O
,    O
erythromycin    O
,    O
sulfadimidine    B-Pyrimidine114999913
,    O
and    O
tetracycline    O
,    O
they    O
were    O
also    O
resistant    O
to    O
trimethoprim    O
.    O

Sulfamethazine    B-Pyrimidine114999913
is    O
another    O
chemical    O
whose    O
concentration    O
has    O
been    O
measured    O
in    O
the    O
waters    O
of    O
Fishing    O
Creek    O
.    O

Sulfadimidine    B-Pyrimidine114999913
,    O
an    O
antibiotic    O
whose    O
abbreviations    O
include    O
SDD    O

Diuretics    O
-    O
furosemide    O
,    O
chlorthalidone    O
,    O
butamide    O
,    O
triamterene    B-Pyrimidine114999913
/    O
hydrochlorothiazide    O

In    O
the    O
United    O
Kingdom    O
,    O
it    O
was    O
also    O
sold    O
in    O
combination    O
with    O
the    O
potassium    O
-    O
sparing    O
diuretic    O
triamterene    B-Pyrimidine114999913
under    O
the    O
trade    O
name    O
Dytide    O
.    O

:*    O
Furesis    O
Comp    O
(    O
"    O
furosemide    O
and    O
triamterene    B-Pyrimidine114999913
"    O
)    O

:*    O
Uretren    O
Comp    O
(    O
"    O
trichlormethiazide    O
and    O
triamterene    B-Pyrimidine114999913
"    O
)    O

Spironolactone    O
(    O
or    O
other    O
distal    O
-    O
tubule    O
diuretics    O
such    O
as    O
triamterene    B-Pyrimidine114999913
or    O
amiloride    O
)    O
is    O
the    O
drug    O
of    O
choice    O
since    O
they    O
block    O
the    O
aldosterone    O
receptor    O
in    O
the    O
collecting    O
tubule    O
.    O

Azoxystrobin    B-Pyrimidine114999913
(    O
brand    O
name    O
Amistar    B-Pyrimidine114999913
,    O
Syngenta    O
)    O
is    O
a    O
systemic    O
fungicide    O
commonly    O
used    O
in    O
agriculture    O
.    O

Key    O
Syngenta    O
brands    O
include    O
Actara    O
(    O
Thiamethoxam    O
)    O
,    O
Agrisure    O
(    O
corn    O
with    O
Viptera    O
trait    O
)    O
,    O
Alto    O
(    O
Cyproconazole    O
)    O
,    O
Amistar    O
(    O
azoxystrobin    B-Pyrimidine114999913
)    O
,    O
Avicta    O
,    O
Axial    O
,    O
Bicep    O
II    O
,    O
Bravo    O
,    O
Callisto    O
,    O
Celest    O
,    O
Cruiser    O
(    O
TMX    O
,    O
Thiamethoxam    O
)    O
,    O
Dividend    O
,    O
Dual    O
,    O
Durivo    O
,    O
Elatus    O
,    O
Fusilade    O
,    O
Force    O
,    O
Golden    O
Harvest    O
,    O
Gramoxone    O
,    O
Hilleshoeg    O
,    O
Karate    O
,    O
Northrup    O
-    O
King    O
(    O
NK    O
)    O
,    O
Proclaim    O
,    O
Revus    O
,    O
Ridomil    O
,    O
Rogers    O
,    O
Score    O
,    O
Seguris    O
,    O
S&G    O
,    O
Tilt    O
,    O
Topik    O
,    O
Touchdown    O
,    O
Vertimec    O
and    O
Vibrance    O
.    O

1993    O
-    O
brodimoprim    B-Pyrimidine114999913

Ro10-5824    B-Pyrimidine114999913
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
dopamine    O
receptor    O
partial    O
agonist    O
selective    O
for    O
the    O
D4    O
subtype    O
,    O
and    O
has    O
nootropic    O
effects    O
in    O
animal    O
studies    O
.    O

Early    O
pesticide    O
development    O
included    O
Gramoxone    O
(    O
1962    O
,    O
a    O
herbicide    O
)    O
,    O
the    O
insecticides    O
pirimiphos-methyl    B-Pyrimidine114999913
in    O
1967    O
and    O
pirimicarb    B-Pyrimidine114999913
in    O
1970    O
,    O
brodifacoum    O
(    O
a    O
rodenticide    O
)    O
was    O
developed    O
in    O
1974    O
;    O
in    O
the    O
late    O
1970s    O
,    O
ICI    O
was    O
involved    O
in    O
the    O
early    O
development    O
of    O
synthetic    O
pyrethroid    O
insecticides    O
such    O
as    O
lambda    O
-    O
cyhalothrin    O
.    O

In    O
chewing    O
gum    O
,    O
zinc    O
acetate    O
is    O
a    O
breath    O
freshener    O
and    O
,    O
when    O
combined    O
with    O
hexetidine    B-Pyrimidine114999913
,    O
a    O
plaque    O
inhibitor    O
.    O

Cyanine    O
derivatives    O
:    O
cyanine    O
,    O
indocarbocyanine    O
,    O
oxacarbocyanine    O
,    O
thiacarbocyanine    O
,    O
and    O
merocyanine    B-Pyrimidine114999913

Quinapyramine    B-Pyrimidine114999913
is    O
a    O
trypanocidal    O
agent    O
for    O
veterinary    O
use    O
.    O

Braf    O
inhibitors    O
(    O
vemurafenib    O
,    O
dabrafenib    B-Pyrimidine114999913
,    O
LGX818    O
)    O
used    O
to    O
treat    O
metastatic    O
melanoma    O
that    O
harbors    O
BRAF    O
V600E    O
mutation    O

Dabrafenib    B-Pyrimidine114999913
(    O
Tafinlar    O
)    O

Fenarimol    B-Pyrimidine114999913
,    O
sold    O
under    O
the    O
tradenames    O
Bloc    B-Pyrimidine114999913
,    O
Rimidin    B-Pyrimidine114999913
and    O
Rubigan    B-Pyrimidine114999913
,    O
is    O
a    O
fungicide    O
which    O
acts    O
against    O
rusts    O
,    O
blackspot    O
and    O
mildew    O
fungi    O
.    O

Pyrazophos    B-Pyrimidine114999913
is    O
an    O
organic    O
compound    O
used    O
as    O
a    O
fungicide    O
and    O
an    O
insecticide    O
.    O

:    O
2-Amino-5-formylamino-6-(5-phospho-D-ribosylamino)pyrimidin-4(3H)-one    B-Pyrimidine114999913
+    O
H2O    O
2,5-diamino-6-(5-phospho-D-ribosylamino)pyrimidin-4(3H)-one    B-Pyrimidine114999913
+    O
formate    O

moxonidine    B-Pyrimidine114999913
(    O
INN    O
)    O

The    O
PyrG    O
gene    O
encodes    O
a    O
CTP    O
synthase    O
,    O
which    O
is    O
involved    O
in    O
pyrimidine    B-Pyrimidine114999913
biosynthesis    I-Pyrimidine114999913
.    O

The    O
PyrC    O
gene    O
encodes    O
Dihydroorotase    O
,    O
an    O
enzyme    O
involved    O
in    O
pyrimidine    B-Pyrimidine114999913
biosynthesis    I-Pyrimidine114999913
.    O

Pyrimidine    B-Pyrimidine114999913
metabolism    I-Pyrimidine114999913

This    O
enzyme    O
participates    O
in    O
pyrimidine    B-Pyrimidine114999913
metabolism    I-Pyrimidine114999913
.    O

This    O
enzyme    O
participates    O
in    O
pyrimidine    B-Pyrimidine114999913
metabolism    I-Pyrimidine114999913
.    O

Other    O
names    O
in    O
common    O
use    O
include    O
uridylate    O
kinase    O
,    O
UMPK    O
,    O
uridine    O
monophosphate    O
kinase    O
,    O
PyrH    O
,    O
UMP    O
-    O
kinase    O
,    O
and    O
SmbA.    O
This    O
enzyme    O
participates    O
in    O
pyrimidine    B-Pyrimidine114999913
metabolism    I-Pyrimidine114999913
.    O

This    O
enzyme    O
participates    O
in    O
pyrimidine    B-Pyrimidine114999913
metabolism    I-Pyrimidine114999913
.    O

acefurtiamine    B-Pyrimidine114999913
(    O
INN    O
)    O

The    O
DNMT    O
inhibitors    O
5-azacytidine    B-Pyrimidine114999913
and    O
5-aza-20-deoxycytidine    O
mentioned    O
above    O
have    O
both    O
been    O
approved    O
by    O
the    O
FDA    O
for    O
the    O
treatment    O
of    O
various    O
forms    O
of    O
cancer    O
.    O

Vidaza    B-Pyrimidine114999913
(    O
azacitidine    B-Pyrimidine114999913
)    O
in    O
phase    O
III    O
trials    O
for    O
Myelodysplastic    O
Syndromes    O
and    O
AML    O

Low    O
doses    O
of    O
azacitidine    B-Pyrimidine114999913
and    O
its    O
analog    O
decitabine    O
have    O
shown    O
results    O
against    O
cancer    O
through    O
epigenetic    O
demethylation    O
.    O

The    O
basis    O
for    O
this    O
approach    O
was    O
that    O
5-azacytidine    B-Pyrimidine114999913
-    O
a    O
DNA    O
demethylation    O
reagent    O
-    O
can    O
cause    O
the    O
formation    O
of    O
myogenic    O
,    O
chondrogenic    O
and    O
adipogeni    O
clones    O
in    O
the    O
immortal    O
cell    O
line    O
of    O
mouse    O
embryonic    O
fibroblasts    O
and    O
that    O
the    O
activation    O
of    O
a    O
single    O
gene    O
,    O
later    O
named    O
MyoD1    O
,    O
is    O
sufficient    O
for    O
such    O
reprogramming    O
.    O

mocetinostat    B-Pyrimidine114999913
(    O
USAN    O
,    O
INN    O
)    O

Brivudine    B-Pyrimidine114999913

Brivudine    B-Pyrimidine114999913
(    O
bromovinyldeoxyuridine    O
)    O
,    O
an    O
antiviral    O
drug    O

Drugs    O
:    O
diuretics    O
(    O
e.g.    O
,    O
thiazides    O
,    O
furosemide    O
)    O
,    O
gliptins    O
(    O
e.g.    O
,    O
vildagliptin    O
,    O
sitagliptin    O
,    O
saxagliptin    O
,    O
linagliptin    B-Pyrimidine114999913
)    O
,    O
tetracycline    O
,    O
sulfonamides    O
,    O
estrogens    O
,    O
azathioprine    O
and    O
mercaptopurine    O
,    O
pentamidine    O
,    O
salicylates    O
,    O
steroids    O
,    O
Depakote    O

linagliptin    B-Pyrimidine114999913
(    O
INN    O
)    O

Dihydrouridine    B-Pyrimidine114999913
(    O
abbreviated    O
as    O
D    B-Pyrimidine114999913
,    O
DHU    B-Pyrimidine114999913
,    O
or    O
UH2    B-Pyrimidine114999913
)    O
is    O
a    O
pyrimidine    O
nucleoside    O
which    O
is    O
the    O
result    O
of    O
adding    O
two    O
hydrogen    O
atoms    O
to    O
a    O
uridine    B-Pyrimidine114999913
,    O
making    O
it    O
a    O
fully    O
saturated    O
pyrimidine    O
ring    O
with    O
no    O
remaining    O
double    O
bonds    O
.    O

Malondialdehyde    O
and    O
other    O
thiobarbituric    O
reactive    O
substances    O
(    O
TBARS    O
)    O
condense    O
with    O
two    O
equivalents    O
of    O
thiobarbituric    B-Pyrimidine114999913
acid    I-Pyrimidine114999913
to    O
give    O
a    O
fluorescent    O
red    O
derivative    O
that    O
can    O
be    O
assayed    O
spectrophotometrically    O
.    O

Adenosine    B-Pyrimidine114999913
thiamine    I-Pyrimidine114999913
diphosphate    I-Pyrimidine114999913
(    O
AThDP    O
)    O
,    O
or    O
thiaminylated    O
adenosine    O
diphosphate    O
(    O
ADP    O
)    O
is    O
a    O
naturally    O
occurring    O
thiamine    O
adenine    O
nucleotide    O
.    O

Zalospirone    B-Pyrimidine114999913
(    O
WY-47,846    B-Pyrimidine114999913
)    O
is    O
a    O
selective    O
5-HT1A    O
partial    O
agonist    O
of    O
the    O
azapirone    O
chemical    O
class    O
.    O

Hydramethylnon    B-Pyrimidine114999913
is    O
an    O
organic    O
chemical    O
compound    O
.    O

Prosultiamine    B-Pyrimidine114999913
(    O
Alinamin    B-Pyrimidine114999913
,    O
Binova    B-Pyrimidine114999913
,    O
Jubedel    B-Pyrimidine114999913
,    O
Taketron    B-Pyrimidine114999913
,    O
Thiobeta    B-Pyrimidine114999913
,    O
Thiotiamina    B-Pyrimidine114999913
)    O
,    O
also    O
known    O
as    O
thiamine    B-Pyrimidine114999913
propyl    I-Pyrimidine114999913
disulfide    I-Pyrimidine114999913
(    O
TPD    B-Pyrimidine114999913
)    O
,    O
is    O
a    O
disulfide    O
thiamine    O
derivative    O
developed    O
in    O
Japan    O
in    O
the    O
1950s    O
as    O
a    O
treatment    O
for    O
vitamin    O
B1    O
deficiency    O
.    O

The    O
compound    O
may    O
be    O
used    O
in    O
combination    O
with    O
other    O
herbicides    O
such    O
as    O
atrazine    O
,    O
2,4-D    O
,    O
bromacil    B-Pyrimidine114999913
,    O
diuron    O
,    O
and    O
sodium    O
metaborate    O
.    O

:    O
J01ED04    O
Sulfametoxydiazine    B-Pyrimidine114999913

Piribedil    B-Pyrimidine114999913
–    O
also    O
D3    O
receptor    O
agonist    O
and    O
α2–adrenergic    O
antagonist    O

Piribedil    B-Pyrimidine114999913
-    O
antiparkinsonian    O
agent    O

Dopamine    O
agonists    O
include    O
bromocriptine    O
,    O
pergolide    O
,    O
pramipexole    O
,    O
ropinirole    O
,    O
piribedil    B-Pyrimidine114999913
,    O
cabergoline    O
,    O
apomorphine    O
and    O
lisuride    O
.    O

CP-809101    B-Pyrimidine114999913
is    O
a    O
drug    O
which    O
acts    O
as    O
a    O
potent    O
and    O
selective    O
5-HT2C    O
receptor    O
agonist    O
.    O

Gemigliptin    B-Pyrimidine114999913
is    O
a    O
dipeptidyl    O
peptidase-4    O
inhibitor    O
developed    O
by    O
LG    O
Life    O
Sciences    O
to    O
treat    O
hyperglycemia    O
in    O
patients    O
with    O
type    O
2    O
diabetes    O
mellitus    O
.    O

2,4-Diaminopyrimidine    B-Pyrimidine114999913

nicarbazin    B-Pyrimidine114999913

Nicarbazin    B-Pyrimidine114999913
is    O
a    O
coccidiostat    O
used    O
on    O
meat    O
chickens    O
.    O

heptabarb    B-Pyrimidine114999913
(    O
INN    O
)    O

Sunepitron    B-Pyrimidine114999913

Lurasidone    O
is    O
chemically    O
similar    O
to    O
Perospirone    O
(    O
also    O
a    O
chemical    O
analogue    O
of    O
Zeldox    O
)    O
,    O
as    O
well    O
as    O
Risperidone    B-Pyrimidine114999913
,    O
Paliperidone    B-Pyrimidine114999913
and    O
Iloperidone    O
.    O

In    O
animal    O
studies    O
,    O
it    O
reversed    O
dizocilpine    O
-    O
induced    O
learning    O
and    O
memory    O
impairment    O
and    O
was    O
found    O
to    O
be    O
superior    O
in    O
doing    O
this    O
to    O
all    O
of    O
the    O
other    O
antipsychotics    O
examined    O
,    O
including    O
risperidone    B-Pyrimidine114999913
,    O
olanzapine    O
,    O
quetiapine    O
,    O
clozapine    O
,    O
aripiprazole    O
,    O
and    O
haloperidol    O
.    O

Risperidone    B-Pyrimidine114999913

Risperidone    B-Pyrimidine114999913

Risperidone    B-Pyrimidine114999913

Risperidone    B-Pyrimidine114999913
(    O
Risperdal    O
)    O

Active    O
substance    O
:    O
risperidone    B-Pyrimidine114999913
)    O

Risperdal    O
(    O
risperidone    B-Pyrimidine114999913
)    O

Juries    O
in    O
several    O
US    O
states    O
have    O
found    O
that    O
Janssen    O
Pharmaceutical    O
and    O
its    O
parent    O
company    O
Johnson    O
&    O
Johnson    O
deceptively    O
promoted    O
the    O
antipsychotic    O
drug    O
Risperdal    B-Pyrimidine114999913
(    O
risperidone    O
)    O
.    O

Tends    O
to    O
produce    O
a    O
moderate    O
amount    O
of    O
sedation    O
,    O
less    O
than    O
clozapine    O
and    O
chlorpromazine    O
but    O
more    O
than    O
aripiprazole    O
,    O
amisulpride    O
,    O
paliperidone    B-Pyrimidine114999913
and    O
sertindole    O
and    O
approximately    O
that    O
of    O
quetiapine    O
and    O
risperidone    B-Pyrimidine114999913
.    O

It    O
tends    O
to    O
produce    O
hyperolactinaemia    O
less    O
often    O
than    O
risperidone    B-Pyrimidine114999913
,    O
paliperidone    B-Pyrimidine114999913
and    O
the    O
typical    O
antipsychotics    O
but    O
more    O
often    O
than    O
quetiapine    O
and    O
clozapine    O
.    O

Of    O
these    O
,    O
risperidone    B-Pyrimidine114999913
is    O
the    O
most    O
notorious    O
for    O
causing    O
this    O
complication    O
.    O

At    O
the    O
time    O
of    O
her    O
death    O
,    O
she    O
had    O
been    O
taking    O
the    O
medications    O
Depakote    O
and    O
Risperdal    B-Pyrimidine114999913
to    O
stabilize    O
her    O
mood    O
.    O

In    O
contrast    O
to    O
older    O
sedating    O
drugs    O
acting    O
on    O
5-HT2A    O
receptors    O
(    O
e.g.    O
,    O
mirtazapine    O
,    O
clozapine    O
,    O
risperidone    B-Pyrimidine114999913
)    O
,    O
eplivanserin    O
has    O
practically    O
no    O
affinity    O
to    O
dopamine    O
,    O
histamine    O
and    O
adrenergic    O
receptors    O
.    O

The    O
D2    O
receptor    O
is    O
involved    O
in    O
the    O
regulation    O
of    O
prolactin    O
secretion    O
,    O
and    O
agonists    O
of    O
the    O
receptor    O
such    O
as    O
bromocriptine    O
and    O
cabergoline    O
decrease    O
prolactin    O
levels    O
while    O
antagonists    O
of    O
the    O
receptor    O
such    O
as    O
domperidone    O
,    O
metoclopramide    O
,    O
haloperidol    O
,    O
risperidone    B-Pyrimidine114999913
,    O
and    O
sulpiride    O
increase    O
prolactin    O
levels    O
.    O

Risperidone    B-Pyrimidine114999913

Risperidone    B-Pyrimidine114999913

The    O
results    O
of    O
a    O
clinical    O
trial    O
examining    O
the    O
efficacy    O
,    O
tolerability    O
and    O
safety    O
of    O
adjunctive    O
pimavanserin    O
to    O
risperidone    B-Pyrimidine114999913
and    O
haloperidol    O
were    O
published    O
in    O
November    O
2012    O
,    O
and    O
the    O
results    O
showed    O
that    O
pimavanserin    O
potentiated    O
the    O
antipsychotic    O
effects    O
of    O
subtherapeutic    O
doses    O
of    O
risperidone    B-Pyrimidine114999913
and    O
improved    O
the    O
tolerability    O
of    O
haloperidol    O
treatment    O
by    O
reducing    O
the    O
incidence    O
of    O
extrapyramidal    O
symptoms    O
.    O

"    O
Anderson    O
Cooper    O
"    O
on    O
CNN    O
in    O
2011    O
revealed    O
video    O
footage    O
of    O
the    O
incident    O
and    O
his    O
mother    O
—    O
with    O
help    O
from    O
a    O
former    O
teacher    O
who    O
used    O
to    O
work    O
at    O
JRC    O
—    O
launching    O
a    O
civil    O
lawsuit    O
against    O
the    O
center    O
after    O
noting    O
having    O
"    O
signed    O
approval    O
for    O
the    O
electric    O
shocks    O
if    O
it    O
ever    O
got    O
to    O
the    O
point    O
where    O
they    O
could    O
n't    O
restrain    O
him    O
"    O
and    O
how    O
the    O
school    O
physician    O
took    O
him    O
off    O
Risperdal    B-Pyrimidine114999913
,    O
an    O
FDA    O
-    O
approved    O
antipsychotic    O
medication    O
for    O
the    O
treatment    O
of    O
autism    O
spectrum    O
disorder    O
(    O
ASD    O
)    O
,    O
twice    O
.    O

vinylbital    B-Pyrimidine114999913

Designed    O
to    O
regulate    O
amphetamines    O
,    O
barbiturates    O
,    O
and    O
other    O
synthetics    O
,    O
the    O
34th    O
version    O
of    O
the    O
treaty    O
,    O
,    O
regulates    O
secobarbital    O
as    O
schedule    O
II    O
,    O
amobarbital    O
,    O
butalbital    O
,    O
cyclobarbital    O
,    O
and    O
pentobarbital    O
as    O
schedule    O
III    O
,    O
and    O
allobarbital    B-Pyrimidine114999913
,    O
barbital    O
,    O
butobarbital    O
,    O
mephobarbital    B-Pyrimidine114999913
,    O
phenobarbital    O
,    O
butabarbital    B-Pyrimidine114999913
,    O
and    O
vinylbital    B-Pyrimidine114999913
as    O
schedule    O
IV    O
on    O
its    O
"    O
Green    O
List    O
"    O
.    O

allobarbital    B-Pyrimidine114999913

Designed    O
to    O
regulate    O
amphetamines    O
,    O
barbiturates    O
,    O
and    O
other    O
synthetics    O
,    O
the    O
34th    O
version    O
of    O
the    O
treaty    O
,    O
,    O
regulates    O
secobarbital    O
as    O
schedule    O
II    O
,    O
amobarbital    O
,    O
butalbital    O
,    O
cyclobarbital    O
,    O
and    O
pentobarbital    O
as    O
schedule    O
III    O
,    O
and    O
allobarbital    B-Pyrimidine114999913
,    O
barbital    O
,    O
butobarbital    O
,    O
mephobarbital    B-Pyrimidine114999913
,    O
phenobarbital    O
,    O
butabarbital    B-Pyrimidine114999913
,    O
and    O
vinylbital    B-Pyrimidine114999913
as    O
schedule    O
IV    O
on    O
its    O
"    O
Green    O
List    O
"    O
.    O

Non    O
-    O
covalent    O
activators    O
of    O
TRPA1    O
also    O
exists    O
,    O
such    O
as    O
methyl    O
salicylate    O
in    O
winter    O
green    O
oil    O
and    O
the    O
synthetic    O
compound    O
PF-4840154    B-Pyrimidine114999913
.    O

Lapatinib    B-Pyrimidine114999913
(    O
Tykerb    O
)    O

Important    O
role    O
(    O
David    O
Cameron    O
as    O
joint    O
global    O
Chief    O
Investigator    O
)    O
in    O
the    O
pivotal    O
clinical    O
trial    O
that    O
tested    O
the    O
hypothesis    O
that    O
the    O
combination    O
of    O
lapatinib    B-Pyrimidine114999913
and    O
the    O
cytotoxic    O
drug    O
capecitabine    B-Pyrimidine114999913
would    O
be    O
superior    O
to    O
capecitabine    O
alone    O
in    O
patients    O
with    O
HER2    O
+    O
metastatic    O
breast    O
cancer    O
that    O
had    O
progressed    O
despite    O
trastuzumab    O
treatment    O
.    O

The    O
results    O
of    O
this    O
trial    O
has    O
led    O
to    O
a    O
global    O
(    O
more    O
than    O
100    O
countries    O
)    O
marketing    O
authorisation    O
of    O
the    O
drug    O
lapatinib    B-Pyrimidine114999913
produced    O
by    O
the    O
pharmaceutical    O
company    O
GlaxoSmithKline    O
.    O

butabarbital    B-Pyrimidine114999913

Designed    O
to    O
regulate    O
amphetamines    O
,    O
barbiturates    O
,    O
and    O
other    O
synthetics    O
,    O
the    O
34th    O
version    O
of    O
the    O
treaty    O
,    O
,    O
regulates    O
secobarbital    O
as    O
schedule    O
II    O
,    O
amobarbital    O
,    O
butalbital    O
,    O
cyclobarbital    O
,    O
and    O
pentobarbital    O
as    O
schedule    O
III    O
,    O
and    O
allobarbital    B-Pyrimidine114999913
,    O
barbital    O
,    O
butobarbital    O
,    O
mephobarbital    B-Pyrimidine114999913
,    O
phenobarbital    O
,    O
butabarbital    B-Pyrimidine114999913
,    O
and    O
vinylbital    B-Pyrimidine114999913
as    O
schedule    O
IV    O
on    O
its    O
"    O
Green    O
List    O
"    O
.    O

A    O
number    O
of    O
treatments    O
have    O
been    O
investigated    O
in    O
the    O
past    O
for    O
IPF    O
,    O
including    O
interferon    O
gamma-1β    O
,    O
bosentan    B-Pyrimidine114999913
,    O
ambrisentan    B-Pyrimidine114999913
,    O
and    O
anticoagulants    O
,    O
but    O
these    O
are    O
no    O
longer    O
considered    O
effective    O
treatment    O
options    O
.    O

selective    O
ETA    O
receptor    O
antagonists    O
(    O
sitaxentan    O
,    O
ambrisentan    B-Pyrimidine114999913
,    O
atrasentan    O
,    O
BQ-123    O
,    O
zibotentan    O
)    O
,    O
which    O
affect    O
endothelin    O
A    O
receptors    O
.    O

Mesoxalic    O
acid    O
can    O
be    O
obtained    O
synthetically    O
by    O
hydrolysis    O
of    O
alloxan    B-Pyrimidine114999913
with    O
baryta    O
water    O
,    O
by    O
warming    O
caffuric    O
acid    O
with    O
lead    O
acetate    O
solution    O
,    O
or    O
from    O
glycerin    O
diacetate    O
and    O
concentrated    O
nitric    O
acid    O
in    O
the    O
cold    O
.    O

It    O
may    O
be    O
prepared    O
by    O
heating    O
alloxantin    B-Pyrimidine114999913
in    O
ammonia    O
gas    O
to    O
100    O
°C    O
,    O
or    O
by    O
boiling    O
uramil    O
(    O
5-aminobarbituric    O
acid    O
)    O
with    O
mercury    O
oxide    O
.    O

It    O
may    O
also    O
be    O
prepared    O
by    O
digesting    O
alloxan    B-Pyrimidine114999913
with    O
alcoholic    O
ammonia    O
at    O
about    O
78    O
°C    O
;    O
the    O
purple    O
solid    O
so    O
formed    O
is    O
easily    O
soluble    O
in    O
water    O
,    O
and    O
the    O
solution    O
produced    O
is    O
indistinguishable    O
from    O
one    O
of    O
murexide    O
.    O

Sulbutiamine    B-Pyrimidine114999913

There    O
are    O
six    O
treatment    O
options    O
approved    O
by    O
the    O
U.S.    O
Food    O
and    O
Drug    O
Administration    O
(    O
FDA    O
)    O
available    O
for    O
persons    O
with    O
a    O
chronic    O
hepatitis    O
B    O
infection    O
:    O
alpha    O
-    O
interferon    O
,    O
pegylated    O
interferon    O
,    O
adefovir    O
,    O
entecavir    O
,    O
telbivudine    B-Pyrimidine114999913
,    O
and    O
lamivudine    O
.    O

LdT    O
,    O
Telbivudine    B-Pyrimidine114999913
(    O
Tyzeka    O
)    O
,    O
a    O
drug    O
for    O
the    O
treatment    O
of    O
chronic    O
hepatitis    O
B    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP    O
-    O
glucose    O
and    O
vitexin    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UDP    B-Pyrimidine114999913
and    O
vitexin    O
2"-O    O
-    O
beta    O
-    O
D    O
-    O
glucoside    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP    O
-    O
glucose    O
and    O
vomilenine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UDP    B-Pyrimidine114999913
and    O
raucaffricine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP    O
-    O
galactose    O
and    O
O    O
-    O
beta    O
-    O
D    O
-    O
xylosylprotein    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UDP    B-Pyrimidine114999913
and    O
4-beta    O
-    O
D    O
-    O
galactosyl    O
-    O
O    O
-    O
beta    O
-    O
D    O
-    O
xylosylprotein    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP    O
-    O
D    O
-    O
xylose    O
and    O
zeatin    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UDP    B-Pyrimidine114999913
and    O
O    O
-    O
beta    O
-    O
D    O
-    O
xylosylzeatin    O
.    O

The    O
substrates    O
for    O
RNR    O
are    O
ADP    O
,    O
GDP    O
,    O
CDP    B-Pyrimidine114999913
and    O
UDP    B-Pyrimidine114999913
.    O

Matching    O
these    O
structural    O
relationships    O
,    O
GPR17    O
has    O
been    O
reported    O
to    O
be    O
activated    O
by    O
cysteinyl    O
leukotrienes    O
(    O
i.e.    O
LTC4    O
and    O
LTD4    O
)    O
as    O
well    O
as    O
the    O
purines    O
(    O
i.e.    O
,    O
uridine    B-Pyrimidine114999913
,    O
Uridine    B-Pyrimidine114999913
diphosphate    I-Pyrimidine114999913
(    O
UDP    O
)    O
,    O
UDP    O
-    O
glucose    O
)    O
.    O

Studies    O
focusing    O
on    O
nerve    O
tissue    O
indicate    O
that    O
GPR17    O
is    O
:    O
a    O
)    O
highly    O
expressed    O
in    O
precursors    O
to    O
mature    O
oligodendrocytes    O
but    O
not    O
expressed    O
in    O
mature    O
oligodendrocytes    O
,    O
suggesting    O
that    O
GPR17    O
must    O
be    O
down    O
-    O
regulated    O
in    O
order    O
for    O
precursor    O
cells    O
to    O
proceed    O
to    O
terminal    O
oligodendrocyte    O
differentiation    O
;    O
b    O
)    O
activated    O
by    O
uridine    B-Pyrimidine114999913
,    O
Uridine    B-Pyrimidine114999913
diphosphate    I-Pyrimidine114999913
(    O
UDP    O
)    O
and    O
UDP    O
-    O
glucose    O
to    O
stimulate    O
outward    O
K+    O
channels    O
and    O
the    O
aforementioned    O
maturation    O
responses    O
in    O
oligodenrocyte    O
precursor    O
cells    O
;    O
c    O
)    O
also    O
activated    O
by    O
LTC4    O
and    O
LTD4    O
;    O
d    O
)    O
more    O
highly    O
expressed    O
in    O
central    O
nervous    O
system    O
(    O
CNS    O
)    O
tissues    O
of    O
animal    O
models    O
undergoing    O
ischemia    O
,    O
Experimental    O
autoimmune    O
encephalomyelitis    O
,    O
and    O
focal    O
demyelination    O
as    O
well    O
as    O
in    O
the    O
CNS    O
tissues    O
of    O
humans    O
suffering    O
brain    O
damage    O
due    O
to    O
ischemia    O
,    O
trauma    O
,    O
and    O
multiple    O
sclerosis    O
;    O
e    O
)    O
expressed    O
in    O
injured    O
neurons    O
and    O
associated    O
with    O
the    O
rapid    O
death    O
and    O
clearance    O
of    O
these    O
neurons    O
in    O
a    O
model    O
of    O
mouse    O
spinal    O
cord    O
crush    O
injury    O
;    O
f    O
)    O
acts    O
to    O
reduce    O
the    O
extent    O
of    O
spinal    O
cord    O
injury    O
in    O
the    O
latter    O
model    O
based    O
on    O
the    O
increased    O
extent    O
of    O
injury    O
in    O
GPR17-depleted    O
mice    O
;    O
and    O
g    O
)    O
acts    O
to    O
reduce    O
inflammation    O
,    O
elevate    O
hippocampus    O
neurogenesis    O
,    O
and    O
improve    O
learning    O
and    O
memory    O
in    O
a    O
rat    O
model    O
of    O
age    O
-    O
related    O
cognitive    O
impairment    O
based    O
on    O
the    O
effects    O
of    O
the    O
GPR17    O
antagonist    O
,    O
montelukast    O
,    O
as    O
well    O
as    O
of    O
GPR17    O
depletion    O
.    O

This    O
receptor    O
is    O
responsive    O
to    O
UDP    B-Pyrimidine114999913
,    O
partially    O
responsive    O
to    O
UTP    B-Pyrimidine114999913
and    O
ADP    O
,    O
and    O
not    O
responsive    O
to    O
ATP    O
.    O

Before    O
monosaccharide    O
units    O
are    O
incorporated    O
into    O
glycoproteins    O
,    O
polysaccharides    O
,    O
or    O
lipids    O
in    O
living    O
organisms    O
,    O
they    O
are    O
typically    O
first    O
"    O
activated    O
"    O
by    O
being    O
joined    O
via    O
a    O
glycosidic    O
bond    O
to    O
the    O
phosphate    O
group    O
of    O
a    O
nucleotide    O
such    O
as    O
uridine    B-Pyrimidine114999913
diphosphate    I-Pyrimidine114999913
(    O
UDP    O
)    O
,    O
guanosine    O
diphosphate    O
(    O
GDP    O
)    O
,    O
thymidine    B-Pyrimidine114999913
diphosphate    I-Pyrimidine114999913
(    O
TDP    O
)    O
,    O
or    O
cytidine    B-Pyrimidine114999913
monophosphate    I-Pyrimidine114999913
(    O
CMP    O
)    O
.    O

Once    O
the    O
incoming    O
galactose    O
has    O
been    O
converted    O
into    O
galactose    O
1-phosphate    O
(    O
Gal-1-P    O
)    O
,    O
it    O
is    O
involved    O
in    O
a    O
reaction    O
with    O
UDP    O
-    O
glucose    O
,    O
a    O
glucose    O
molecule    O
bonded    O
to    O
uridine    B-Pyrimidine114999913
diphosphate    I-Pyrimidine114999913
(    O
UDP    O
)    O
.    O

They    O
can    O
do    O
this    O
by    O
way    O
of    O
reglucosylating    O
these    O
glycoproteins    O
by    O
an    O
enzyme    O
called    O
UDP    B-Pyrimidine114999913
-    O
glucose    O
-    O
glycoprotein    O
glucosyltransferase    O
.    O

The    O
crystal    O
structure    O
of    O
O    O
-    O
GlcNAc    O
transferase    O
has    O
not    O
been    O
well    O
studied    O
,    O
but    O
the    O
structure    O
of    O
a    O
binary    O
complex    O
with    O
UDP    O
and    O
a    O
ternary    O
complex    O
with    O
UDP    B-Pyrimidine114999913
and    O
a    O
peptide    O
substrate    O
has    O
been    O
researched    O
.    O

Uridine    B-Pyrimidine114999913
diphosphate    I-Pyrimidine114999913
,    O
abbreviated    O
UDP    B-Pyrimidine114999913
,    O
is    O
a    O
nucleotide    O
diphosphate    O
.    O

UDP    B-Pyrimidine114999913

Uridine    O
diphosphate    O
galactose    O
(    O
UDP    B-Pyrimidine114999913
-    O
galactose    O
)    O
is    O
an    O
intermediate    O
in    O
the    O
production    O
of    O
polysaccharides    O
.    O

Uridine    B-Pyrimidine114999913
diphosphate    I-Pyrimidine114999913

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
UMP    B-Pyrimidine114999913
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
UDP    B-Pyrimidine114999913
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP    O
-    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
galactosamine    O
and    O
glycoprotein    O
-    O
alpha    O
-    O
L    O
-    O
fucosyl-(1,2)-D    O
-    O
galactose    O
,    O
whereas    O
its    O
3    O
products    O
are    O
UDP    B-Pyrimidine114999913
,    O
[    O
[    O
glycoprotein    O
-    O
N    O
-    O
acetyl    O
-    O
alpha    O
-    O
D    O
-    O
galactosaminyl-(1,3)-[alpha    O
-    O
L    O
-    O
fucosyl-    O
]    O
]    O
,    O
and    O
[    O
[    O
(    O
1,2)]-D    O
-    O
galactose    O
]    O
]    O
.    O

File    O
:    O
Clevudine    O
Clevudine    B-Pyrimidine114999913

dual    O
antagonists    O
(    O
bosentan    B-Pyrimidine114999913
,    O
macitentan    O
,    O
tezosentan    B-Pyrimidine114999913
)    O
,    O
which    O
affect    O
both    O
endothelin    O
A    O
and    O
B    O
receptors    O
.    O

Fursultiamine    B-Pyrimidine114999913
(    O
INN    O
;    O
Adventan    B-Pyrimidine114999913
,    O
Alinamin-F    B-Pyrimidine114999913
,    O
Benlipoid    B-Pyrimidine114999913
,    O
Bevitol    B-Pyrimidine114999913
Lipophil    I-Pyrimidine114999913
,    O
Judolor    B-Pyrimidine114999913
,    O
Lipothiamine    B-Pyrimidine114999913
)    O
,    O
chemically    O
thiamine    B-Pyrimidine114999913
tetrahydrofurfuryl    I-Pyrimidine114999913
disulfide    I-Pyrimidine114999913
(    O
TTFD    B-Pyrimidine114999913
)    O
,    O
is    O
a    O
disulfide    O
derivative    O
of    O
thiamine    O
,    O
or    O
an    O
allithiamine    B-Pyrimidine114999913
.    O

Poly    O
I    O
:    O
C    O
is    O
a    O
mismatched    O
double    O
-    O
stranded    O
RNA    O
with    O
one    O
strand    O
being    O
a    O
polymer    O
of    O
inosinic    O
acid    O
,    O
the    O
other    O
a    O
polymer    O
of    O
cytidylic    B-Pyrimidine114999913
acid    I-Pyrimidine114999913
.    O

They    O
are    O
synthesized    O
by    O
the    O
addition    O
of    O
cytidine    B-Pyrimidine114999913
diphosphate    I-Pyrimidine114999913
-    O
ethanolamine    O
to    O
diglycerides    O
,    O
releasing    O
cytidine    B-Pyrimidine114999913
monophosphate    I-Pyrimidine114999913
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CDP    O
-    O
diacylglycerol    O
and    O
choline    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CMP    B-Pyrimidine114999913
and    O
phosphatidylcholine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CDP    O
-    O
ethanolamine    O
and    O
L    O
-    O
serine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CMP    B-Pyrimidine114999913
and    O
L    O
-    O
serine    O
-    O
phosphoethanolamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CDP    O
-    O
choline    O
and    O
sphingosine    O
,    O
whereas    O
its    O
two    O
products    O
are    O
CMP    B-Pyrimidine114999913
and    O
sphingosyl    O
-    O
phosphocholine    O
.    O

Diaminopyrimidines    B-Pyrimidine114999913
are    O
a    O
class    O
of    O
organic    O
chemical    O
compounds    O
that    O
include    O
two    O
amine    O
groups    O
on    O
a    O
pyrimidine    O
ring    O
.    O

Syk    O
inhibitor    O
fostamatinib    B-Pyrimidine114999913
is    O
in    O
trials    O
.    O

:    O
D04AA01    O
Thonzylamine    B-Pyrimidine114999913

Thymidylate    O
synthetase    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
conversion    O
of    O
deoxyuridine    B-Pyrimidine114999913
monophosphate    I-Pyrimidine114999913
(    O
dUMP    O
)    O
to    O
deoxythymidine    B-Pyrimidine114999913
monophosphate    I-Pyrimidine114999913
(    O
dTMP    O
)    O
.    O

Dihydrofolate    O
reductase    O
converts    O
dihydrofolate    O
into    O
tetrahydrofolate    O
,    O
a    O
methyl    O
group    O
shuttle    O
required    O
for    O
the    O
de    O
novo    O
synthesis    O
of    O
purines    O
,    O
thymidylic    B-Pyrimidine114999913
acid    I-Pyrimidine114999913
,    O
and    O
certain    O
amino    O
acids    O
.    O

Tetrahydrofolate    O
and    O
its    O
derivatives    O
are    O
essential    O
for    O
purine    O
and    O
thymidylate    B-Pyrimidine114999913
synthesis    O
,    O
which    O
are    O
important    O
for    O
cell    O
proliferation    O
and    O
cell    O
growth    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
,    O
dGMP    O
,    O
and    O
dTMP    B-Pyrimidine114999913
,    O
whereas    O
its    O
3    O
products    O
are    O
ADP    O
,    O
dGDP    O
,    O
and    O
dTDP    B-Pyrimidine114999913
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
thymidylate    B-Pyrimidine114999913
and    O
H2O    O
,    O
whereas    O
its    O
two    O
products    O
are    O
thymidine    O
and    O
phosphate    O
.    O

F    O
–    O
fluorouracil    O
(    O
5-FU    O
)    O
,    O
a    O
pyrimidine    B-Pyrimidine114999913
analog    I-Pyrimidine114999913
and    O
antimetabolite    O
which    O
incorporates    O
into    O
the    O
DNA    O
molecule    O
and    O
stops    O
DNA    O
synthesis    O
;    O

Pyrimidine    B-Pyrimidine114999913
analogue    I-Pyrimidine114999913
of    O
uridine    B-Pyrimidine114999913
:    O
Idoxuridine    O
,    O
Trifluridine    B-Pyrimidine114999913

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dTTP    B-Pyrimidine114999913
and    O
alpha    O
-    O
D    O
-    O
galactose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
dTDP    O
-    O
galactose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
dTTP    B-Pyrimidine114999913
and    O
alpha    O
-    O
D    O
-    O
glucose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
pyrophosphate    O
and    O
dTDP    O
-    O
glucose    O
.    O

T7    O
DNA    O
helicase    O
is    O
a    O
hexameric    O
motor    O
protein    O
that    O
uses    O
energy    O
from    O
dTTP    B-Pyrimidine114999913
hydrolysis    O
to    O
process    O
unidirectionally    O
along    O
single    O
stranded    O
DNA    O
,    O
separating    O
the    O
two    O
strands    O
as    O
it    O
progresses    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
dCMP    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
dCDP    B-Pyrimidine114999913
.    O

Lotusate    B-Pyrimidine114999913

File    O
:    O
Sorivudine    B-Pyrimidine114999913

It    O
is    O
isomeric    O
with    O
other    O
naphthyridines    O
including    O
quinazoline    B-Pyrimidine114999913
,    O
phthalazine    O
and    O
cinnoline    O
.    O

It    O
is    O
isomeric    O
with    O
other    O
naphthyridines    O
including    O
quinoxaline    O
,    O
cinnoline    O
and    O
quinazoline    B-Pyrimidine114999913
.    O

Bosutinib    O
's    O
structure    O
is    O
based    O
on    O
a    O
quinoline    O
scaffold    O
and    O
is    O
structurally    O
related    O
to    O
the    O
AstraZeneca    O
quinazoline    B-Pyrimidine114999913
template    O
.    O

:    O
A11DA03    O
Benfotiamine    B-Pyrimidine114999913

Lanosterol    O
14α-demethylase    O
(    O
CYP51A1    O
)    O
inhibitors    O
such    O
as    O
clotrimazole    O
,    O
fluconazole    O
,    O
itraconazole    O
,    O
ketoconazole    O
,    O
miconazole    O
,    O
and    O
voriconazole    B-Pyrimidine114999913
prevent    O
the    O
production    O
of    O
ergosterol    O
from    O
lanosterol    O
.    O

Also    O
,    O
antifungal    O
drug    O
therapy    O
and    O
surgical    O
excision    O
can    O
be    O
used    O
to    O
treat    O
the    O
infection    O
separately    O
or    O
together    O
.    O
"    O
O.    O
gallopava    O
"    O
infection    O
treatment    O
widely    O
use    O
antifungal    O
drugs    O
such    O
as    O
amphotericin    O
B    O
,    O
itraconazole    O
,    O
triazole    O
,    O
voriconazole    B-Pyrimidine114999913
,    O
fluconazole    O
,    O
posaconazole    O
,    O
and    O
many    O
others    O
.    O

"    O
In    O
vitro    O
"    O
antifungal    O
susceptibility    O
tests    O
of    O
the    O
entire    O
genus    O
"    O
Apophysomyces    O
"    O
have    O
revealed    O
that    O
amphotericin    O
B    O
and    O
posaconazole    O
are    O
the    O
most    O
effective    O
against    O
"    O
A.    O
variabilis    O
"    O
infections    O
when    O
compared    O
to    O
itraconazole    O
,    O
ravuconazole    O
,    O
and    O
voriconazole    B-Pyrimidine114999913
.    O
Testing    O
data    O
has    O
also    O
showed    O
that    O
caspofungin    O
and    O
anidulafungin    O
are    O
inactive    O
antifungal    O
agents    O
against    O
all    O
strains    O
of    O
the    O
genus    O
"    O
Apophysomyces    O
"    O
.    O

It    O
's    O
also    O
contraindicated    O
if    O
patient    O
is    O
taking    O
Macrolide    O
antibiotics    O
(    O
eg    O
,    O
erythromycin    O
)    O
,    O
certain    O
HIV    O
protease    O
inhibitors    O
(    O
eg    O
,    O
ritonavir    O
,    O
nelfinavir    O
,    O
indinavir    O
)    O
,    O
certain    O
azole    O
antifungals    O
(    O
eg    O
,    O
ketoconazole    O
,    O
itraconazole    O
,    O
voriconazole    B-Pyrimidine114999913
)    O
delavirdine    O
,    O
efavirenz    O
or    O
a    O
5-HT1    O
agonist    O
(    O
eg    O
,    O
sumatriptan    O
)    O
.    O

Antifungals    O
-    O
voriconazole    B-Pyrimidine114999913

The    O
course    O
of    O
treatment    O
has    O
been    O
to    O
prescribe    O
the    O
patient    O
with    O
amphotericin    O
B    O
and    O
voriconazole    B-Pyrimidine114999913
.    O

Caspofungin    O
has    O
some    O
interference    O
with    O
ciclosporin    O
metabolism    O
,    O
and    O
micafungin    O
has    O
some    O
interference    O
with    O
sirolimus    O
(    O
rapamycin    O
)    O
,    O
but    O
anidulafungin    O
needs    O
no    O
dose    O
adjustments    O
when    O
given    O
with    O
ciclosporin    O
,    O
tacrolimus    O
,    O
or    O
voriconazole    B-Pyrimidine114999913
.    O

Drugs    O
such    O
as    O
panitumumab    O
,    O
cetuximab    O
,    O
gefitinib    B-Pyrimidine114999913
,    O
erlotinib    B-Pyrimidine114999913
,    O
afatinib    O
,    O
and    O
lapatinib    O
are    O
used    O
to    O
inhibit    O
it    O
.    O

2004    O
–    O
Tarceva    B-Pyrimidine114999913
(    O
erlotinib    O
)    O
:    O
Treatment    O
for    O
patients    O
with    O
locally    O
advanced    O
or    O
metastatic    O
non    O
-    O
small    O
cell    O
lung    O
cancer    O
,    O
and    O
pancreatic    O
cancer    O
.    O

However    O
,    O
the    O
combination    O
of    O
gemcitabine    O
with    O
erlotinib    B-Pyrimidine114999913
was    O
found    O
to    O
increase    O
survival    O
modestly    O
,    O
and    O
erlotinib    O
was    O
licensed    O
by    O
the    O
FDA    O
for    O
use    O
in    O
pancreatic    O
cancer    O
in    O
2005    O
.    O

The    O
JUNIPER    O
Study    O
is    O
comparing    O
Abemaciclib    O
against    O
Erlotinib    B-Pyrimidine114999913
in    O
patients    O
with    O
stage    O
IV    O
Non    O
-    O
small    O
-    O
cell    O
lung    O
carcinoma    O

Gefitinib    O
is    O
an    O
EGFR    O
inhibitor    O
,    O
like    O
erlotinib    B-Pyrimidine114999913
,    O
which    O
interrupts    O
signaling    O
through    O
the    O
epidermal    O
growth    O
factor    O
receptor    O
(    O
EGFR    O
)    O
in    O
target    O
cells    O
.    O

Genzyme    O
,    O
QIAGEN    O
,    O
Argenomics    O
S.A.    O
&    O
other    O
companies    O
make    O
tests    O
to    O
detect    O
"    O
EGFR    O
"    O
mutations    O
,    O
designed    O
to    O
help    O
predict    O
which    O
lung    O
cancer    O
patients    O
may    O
respond    O
best    O
to    O
some    O
therapies    O
,    O
including    O
gefitinib    O
and    O
erlotinib    B-Pyrimidine114999913
.    O

Erlotinib    B-Pyrimidine114999913
,    O
another    O
EGFR    O
tyrosine    O
kinase    O
inhibitor    O
that    O
has    O
a    O
similar    O
mechanism    O
of    O
action    O
to    O
gefitinib    O
.    O

RS-127,445    B-Pyrimidine114999913

Avitriptan    B-Pyrimidine114999913

Heptobarbital    B-Pyrimidine114999913
(    O
Rutonal    B-Pyrimidine114999913
)    O
,    O
also    O
known    O
as    O
phenylmethylbarbituric    B-Pyrimidine114999913
acid    I-Pyrimidine114999913
is    O
a    O
barbiturate    O
derivative    O
.    O

Tolimidone    B-Pyrimidine114999913
(    O
CP-26154    O
;    O
MLR-1023    O
)    O
is    O
a    O
compound    O
which    O
was    O
discovered    O
by    O
scientists    O
at    O
Pfizer    O
,    O
was    O
found    O
to    O
stimulate    O
secretion    O
of    O
gastric    O
mucosa    O
,    O
and    O
was    O
in    O
development    O
by    O
Pfizer    O
as    O
a    O
drug    O
candidate    O
to    O
treat    O
gastric    O
ulcers    O
but    O
was    O
abandoned    O
.    O

Certain    O
medications    O
,    O
e.g.    O
amiodarone    O
,    O
bleomycin    B-Pyrimidine114999913
(    O
pingyangmycin    B-Pyrimidine114999913
)    O
,    O
busulfan    O
,    O
methotrexate    O
,    O
apomorphine    O
,    O
and    O
nitrofurantoin    O

Quisinostat    B-Pyrimidine114999913
(    O
JNJ-26481585    O
)    O

Alloxan    O
was    O
used    O
in    O
the    O
production    O
of    O
the    O
purple    O
dye    O
murexide    B-Pyrimidine114999913
,    O
discovered    O
by    O
Carl    O
Wilhelm    O
Scheele    O
in    O
1776    O
.    O

Murexide    B-Pyrimidine114999913
(    O
NH4C8H4N5O6    O
,    O
or    O
C8H5N5O6·NH3    O
)    O
,    O
also    O
called    O
ammonium    B-Pyrimidine114999913
purpurate    I-Pyrimidine114999913
or    O
MX    B-Pyrimidine114999913
,    O
is    O
the    O
ammonium    O
salt    O
of    O
purpuric    O
acid    O
.    O

Tetroxoprim    B-Pyrimidine114999913

:    O
J01EB01    O
Sulfaisodimidine    B-Pyrimidine114999913

Dasatinib    B-Pyrimidine114999913
-    O
anticancer    O
agent    O

Dasatinib    B-Pyrimidine114999913
is    O
a    O
thiazolylaminopyrimidine    O
developed    O
as    O
the    O
hydrochloride    O
salt    O
.    O

Crystal    O
structure    O
(    O
PDB    O
2GQG    O
)    O
of    O
Abl    O
kinase    O
domain    O
(    O
blue    O
)    O
in    O
complex    O
with    O
dasatinib    B-Pyrimidine114999913
(    O
red    O
)    O
.    O

In    O
those    O
cases    O
other    O
inhibitors    O
such    O
as    O
dasatinib    B-Pyrimidine114999913
and    O
nilotinib    B-Pyrimidine114999913
can    O
be    O
used    O
.    O

Thymidine    O
can    O
be    O
phosphorylated    O
with    O
up    O
to    O
three    O
phosphoric    O
acid    O
groups    O
,    O
producing    O
dTMP    B-Pyrimidine114999913
(    O
deoxythymidine    O
monophosphate    O
)    O
,    O
dTDP    B-Pyrimidine114999913
,    O
or    O
dTTP    B-Pyrimidine114999913
(    O
for    O
the    O
di-    O
and    O
tri-    O
phosphates    O
,    O
respectively    O
)    O
.    O

The    O
3    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
,    O
dGMP    O
,    O
and    O
dTMP    B-Pyrimidine114999913
,    O
whereas    O
its    O
3    O
products    O
are    O
ADP    O
,    O
dGDP    O
,    O
and    O
dTDP    B-Pyrimidine114999913
.    O

BMY-14802    B-Pyrimidine114999913

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP    O
-    O
glucose    O
and    O
glycoprotein    O
D    O
-    O
mannose    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UMP    B-Pyrimidine114999913
and    O
glycoprotein    O
6-(D    O
-    O
glucose-1-phospho)-D    O
-    O
mannose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
UMP    B-Pyrimidine114999913
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
UDP    B-Pyrimidine114999913
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UDP    O
-    O
galactose    O
and    O
undecaprenyl    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
UMP    B-Pyrimidine114999913
and    O
alpha    O
-    O
D    O
-    O
galactosyl    O
-    O
diphosphoundecaprenol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
uridine    B-Pyrimidine114999913
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
UMP    B-Pyrimidine114999913
.    O

The    O
transferase    O
UDP    O
-    O
glucuronate    O
pyrophosphorylase    O
removes    O
a    O
UMP    B-Pyrimidine114999913
and    O
glucuronokinase    O
,    O
with    O
the    O
cofactor    O
ADP    O
,    O
removes    O
the    O
final    O
phosphate    O
leading    O
to    O
D    O
-    O
glucuronic    O
acid    O
.    O

Barbital    O
,    O
methylphenobarbital    B-Pyrimidine114999913
(    O
also    O
known    O
as    O
mephobarbital    B-Pyrimidine114999913
)    O
,    O
and    O
phenobarbital    O
are    O
designated    O
schedule    O
IV    O
drugs    O
,    O
and    O
"    O
Any    O
substance    O
which    O
contains    O
any    O
quantity    O
of    O
a    O
derivative    O
of    O
barbituric    O
acid    O
,    O
or    O
any    O
salt    O
of    O
a    O
derivative    O
of    O
barbituric    O
acid    O
"    O
(    O
all    O
other    O
barbiturates    O
)    O
were    O
designated    O
as    O
schedule    O
III    O
.    O

Designed    O
to    O
regulate    O
amphetamines    O
,    O
barbiturates    O
,    O
and    O
other    O
synthetics    O
,    O
the    O
34th    O
version    O
of    O
the    O
treaty    O
,    O
,    O
regulates    O
secobarbital    O
as    O
schedule    O
II    O
,    O
amobarbital    O
,    O
butalbital    O
,    O
cyclobarbital    O
,    O
and    O
pentobarbital    O
as    O
schedule    O
III    O
,    O
and    O
allobarbital    B-Pyrimidine114999913
,    O
barbital    O
,    O
butobarbital    O
,    O
mephobarbital    B-Pyrimidine114999913
,    O
phenobarbital    O
,    O
butabarbital    B-Pyrimidine114999913
,    O
and    O
vinylbital    B-Pyrimidine114999913
as    O
schedule    O
IV    O
on    O
its    O
"    O
Green    O
List    O
"    O
.    O

Methylphenobarbital    B-Pyrimidine114999913
,    O

Benzylthiouracil    B-Pyrimidine114999913
,    O
a    O
pharmaceutical    O
compound    O

ticagrelor    B-Pyrimidine114999913

Frequently    O
,    O
aspirin    O
is    O
combined    O
with    O
an    O
ADP    O
receptor    O
inhibitor    O
,    O
such    O
as    O
clopidogrel    O
,    O
prasugrel    O
,    O
or    O
ticagrelor    B-Pyrimidine114999913
to    O
prevent    O
blood    O
clots    O
.    O

With    O
the    O
advent    O
of    O
newer    O
and    O
safer    O
antiplatelet    O
drugs    O
such    O
as    O
clopidogrel    O
and    O
ticagrelor    B-Pyrimidine114999913
,    O
its    O
use    O
remained    O
limited    O
.    O

Oxantel    B-Pyrimidine114999913
is    O
an    O
anthelmintic    O
.    O

Abasol    B-Pyrimidine114999913
(    O
York    O
Pharma    O
)    O

Like    O
udenafil    O
and    O
avanafil    B-Pyrimidine114999913
it    O
belongs    O
to    O
a    O
new    O
generation    O
of    O
PDE5    O
inhibitors    O
.    O

Mirodenafil    O
belongs    O
to    O
the    O
drug    O
class    O
PDE5    O
inhibitors    O
,    O
which    O
includes    O
avanafil    B-Pyrimidine114999913
,    O
sildenafil    O
,    O
tadalafil    O
,    O
udenafil    O
,    O
and    O
vardenafil    O
,    O
and    O
is    O
the    O
first    O
-    O
line    O
treatment    O
for    O
erectile    O
dysfunction    O
.    O

Crimidine    B-Pyrimidine114999913
(    O
inhibits    O
metabolism    O
of    O
vitamin    O
B6    O
)    O

Pteridine    B-Pyrimidine114999913

PAH    O
is    O
one    O
of    O
three    O
members    O
of    O
the    O
biopterin    O
-    O
dependent    O
aromatic    O
amino    O
acid    O
hydroxylases    O
,    O
a    O
class    O
of    O
monooxygenase    O
that    O
uses    O
tetrahydrobiopterin    O
(    O
BH4    O
,    O
a    O
pteridine    B-Pyrimidine114999913
cofactor    O
)    O
and    O
a    O
non    O
-    O
heme    O
iron    O
for    O
catalysis    O
.    O

Source    O
of    O
colouration    O
comes    O
from    O
different    O
pigments    O
within    O
the    O
lizard    O
,    O
with    O
yellow    O
colouration    O
originating    O
from    O
carotenoids    O
,    O
and    O
the    O
expression    O
of    O
red    O
/    O
orange    O
colour    O
from    O
pteridine    B-Pyrimidine114999913
.    O

Base    B-Pyrimidine114999913
J    I-Pyrimidine114999913
(    O
beta    O
-    O
d    O
-    O
glucopyranosyloxymethyluracil    O
)    O
,    O
a    O
modified    O
form    O
of    O
uracil    O
,    O
is    O
also    O
found    O
in    O
several    O
organisms    O
:    O
the    O
flagellates    O
"    O
Diplonema    O
"    O
and    O
"    O
Euglena    O
"    O
,    O
and    O
all    O
the    O
kinetoplastid    O
genera    O
.    O

Tirilazad    B-Pyrimidine114999913
-    O
neuroprotective    O
agent    O

PRPP    O
reacts    O
with    O
orotate    B-Pyrimidine114999913
to    O
form    O
orotidylate    O
,    O
which    O
can    O
be    O
converted    O
to    O
uridylate    B-Pyrimidine114999913
(    O
UMP    O
)    O
.    O

This    O
bifunctional    O
enzyme    O
is    O
named    O
UMP    O
synthase    O
and    O
it    O
also    O
catalyzes    O
the    O
preceding    O
reaction    O
in    O
pyrimidine    O
nucleotide    O
biosynthesis    O
,    O
the    O
transfer    O
of    O
ribose    O
5-phosphate    O
from    O
5-phosphoribosyl-1-pyrophosphate    O
to    O
orotate    B-Pyrimidine114999913
to    O
form    O
OMP    O
.    O

Orotidine    O
is    O
a    O
nucleoside    O
formed    O
by    O
attaching    O
orotic    B-Pyrimidine114999913
acid    I-Pyrimidine114999913
to    O
a    O
ribose    O
ring    O
via    O
a    O
β-N1-glycosidic    O
bond    O
.    O

Orotic    O
aciduria    O
is    O
a    O
disease    O
yielding    O
an    O
excessive    O
excretion    O
of    O
orotic    B-Pyrimidine114999913
acid    I-Pyrimidine114999913
in    O
urine    O
.    O

Butallylonal    B-Pyrimidine114999913
is    O
a    O
barbiturate    O
derivative    O
invented    O
in    O
the    O
1920s    O
.    O

:    O
J01ED06    O
Sulfaperin    B-Pyrimidine114999913

Eptapirone    B-Pyrimidine114999913
-    O
anxiolytic    O

Etravirine    B-Pyrimidine114999913
(    O
TMC125    O
,    O
tradename    O
Intelence    O
)    O
,    O
a    O
non    O
-    O
nucleoside    O
reverse    O
transcriptase    O
inhibitor    O
(    O
NNRTI    O
)    O

Etravirine    B-Pyrimidine114999913
(    O
ETR    B-Pyrimidine114999913
,    O
brand    O
name    O
Intelence    B-Pyrimidine114999913
,    O
formerly    O
known    O
as    O
TMC125    O
)    O
is    O
a    O
drug    O
used    O
for    O
the    O
treatment    O
of    O
HIV    O
.    O

F-15,599    B-Pyrimidine114999913
(    O
research    O
compound    O
,    O
highly    O
potent    O
and    O
selective    O
for    O
5-HT1A    O
)    O

Base    O
analog    O
such    O
as    O
5-bromouracil    B-Pyrimidine114999913
may    O
substitute    O
for    O
thymine    O
in    O
replication    O
.    O

5-Bromouracil    B-Pyrimidine114999913

Flucytosine    B-Pyrimidine114999913
:    O
Toxicity    O
of    O
flucytosine    O
is    O
increased    O
and    O
allows    O
a    O
lower    O
dose    O
of    O
amphotericin    O
B.    O
Amphotericin    O
B    O
may    O
also    O
facilitate    O
entry    O
of    O
flucystosine    O
into    O
the    O
fungal    O
cell    O
by    O
interfering    O
with    O
the    O
permeability    O
of    O
the    O
fungal    O
cell    O
membrane    O
.    O

"    O
Coniochaeta    O
hoffmannii    O
"    O
has    O
proven    O
to    O
be    O
resistant    O
to    O
multiple    O
antifungal    O
agents    O
,    O
including    O
amphotericin    O
B    O
,    O
flucytosine    B-Pyrimidine114999913
,    O
ketoconazole    O
,    O
and    O
fluconazole    O
.    O
Because    O
of    O
this    O
,    O
precautions    O
have    O
been    O
taken    O
,    O
such    O
as    O
antifungal    O
susceptibility    O
testing    O
,    O
in    O
order    O
to    O
circumvent    O
such    O
drawbacks    O
.    O

The    O
addition    O
of    O
oral    O
or    O
intravenous    O
flucytosine    B-Pyrimidine114999913
improves    O
response    O
rates    O
.    O

"    O
Rhodotorula    O
"    O
is    O
most    O
commonly    O
found    O
in    O
patients    O
who    O
are    O
immunosuppressed    O
and/or    O
are    O
using    O
foreign    O
-    O
body    O
technology    O
such    O
as    O
central    O
venous    O
catheters    O
.    O
"    O
Rhodotorula    O
"    O
is    O
commonly    O
treated    O
by    O
removing    O
the    O
catheter    O
and    O
the    O
use    O
of    O
anti    O
-    O
fungals    O
.    O
"    O
Rhodotorula    O
"    O
is    O
susceptible    O
to    O
amphotericin    O
B    O
and    O
Flucytosine    B-Pyrimidine114999913
.    O

In    O
2014    O
it    O
was    O
reported    O
that    O
treatment    O
of    O
"    O
Acanthamoeba    O
"    O
encephalitis    O
in    O
a    O
63-year    O
-    O
old    O
immunosuppressed    O
male    O
was    O
not    O
cured    O
by    O
a    O
combination    O
of    O
miltefosine    O
,    O
sulfadiazine    O
,    O
fluconazole    O
,    O
flucytosine    B-Pyrimidine114999913
,    O
and    O
azithromycin    O
.    O

Pulmonary    O
toxicity    O
,    O
or    O
lung    O
damage    O
,    O
can    O
occur    O
with    O
the    O
use    O
of    O
bleomycin    B-Pyrimidine114999913
in    O
ABVD    O
,    O
especially    O
when    O
radiation    O
therapy    O
to    O
the    O
chest    O
is    O
also    O
given    O
as    O
part    O
of    O
the    O
treatment    O
for    O
Hodgkin    O
's    O
lymphoma    O
.    O

Streptomyces    O
mobaraensis    O
"    O
produces    O
bleomycin    B-Pyrimidine114999913
,    O
detoxin    O
,    O
piericidin    O
A    O
,    O
piericidin    O
B    O
,    O
reticulol    O
and    O
transglutaminase    O
.    O

Exposure    O
to    O
certain    O
chemicals    O
such    O
as    O
salicylic    O
acid    O
,    O
bleomycin    B-Pyrimidine114999913
,    O
and    O
cisplatin    O
.    O

Chemicals    O
such    O
as    O
bleomycin    B-Pyrimidine114999913
,    O
tetracycline    O
(    O
e.g.    O
,    O
minocycline    O
)    O
,    O
povidone    O
-    O
iodine    O
,    O
or    O
a    O
slurry    O
of    O
talc    O
can    O
be    O
introduced    O
into    O
the    O
pleural    O
space    O
through    O
a    O
chest    O
drain    O
.    O

For    O
example    O
,    O
glyoxalase    O
I    O
resembles    O
several    O
proteins    O
that    O
allow    O
bacteria    O
to    O
resist    O
antibiotics    O
such    O
as    O
fosfomycin    O
,    O
bleomycin    B-Pyrimidine114999913
and    O
mitomycin    O
.    O

Phleomycins    O
are    O
a    O
group    O
of    O
glycopeptide    O
antibiotics    O
found    O
in    O
"    O
Streptomycin    O
"    O
which    O
are    O
closely    O
related    O
to    O
bleomycin    B-Pyrimidine114999913
.    O

EP2    O
expression    O
in    O
fibroblasts    O
from    O
the    O
lungs    O
of    O
mice    O
with    O
Bleomycin    B-Pyrimidine114999913
-    O
induced    O
pulmonary    O
fibrosis    O
and    O
humans    O
with    O
Idiopathic    O
pulmonary    O
fibrosis    O
is    O
greatly    O
reduced    O
.    O

"    O
PTGFR    O
"    O
knockout    O
mice    O
also    O
show    O
a    O
reduction    O
in    O
the    O
development    O
of    O
pulmonary    O
fibrosis    O
normally    O
caused    O
by    O
microbial    O
invasion    O
or    O
bleomycin    B-Pyrimidine114999913
treatment    O
.    O

On    O
the    O
other    O
hand    O
,    O
IP    O
receptors    O
may    O
serve    O
to    O
promote    O
non    O
-    O
allergic    O
inflammatory    O
responses    O
:    O
IP    O
receptor    O
-    O
deficient    O
mice    O
exhibited    O
increased    O
lung    O
inflammation    O
in    O
a    O
model    O
of    O
bleomycin    B-Pyrimidine114999913
-    O
induced    O
pulmonary    O
fibrosis    O
while    O
mice    O
made    O
to    O
over    O
-    O
express    O
the    O
PGI2-forming    O
enzyme    O
,    O
Prostacyclin    O
synthase    O
,    O
in    O
their    O
airway    O
epithelial    O
cells    O
were    O
protected    O
against    O
lung    O
injury    O
in    O
this    O
model    O
.    O

Certain    O
drugs    O
such    O
as    O
amiodarone    O
,    O
bleomycin    B-Pyrimidine114999913
and    O
methotrexate    O
.    O

Exposure    O
of    O
"    O
Sulfolobus    O
solfataricus    O
"    O
to    O
the    O
DNA    O
damaging    O
agents    O
UV    O
-    O
irradiation    O
,    O
bleomycin    B-Pyrimidine114999913
or    O
mitomycin    O
C    O
induces    O
cellular    O
aggregation    O
.    O

denufosol    B-Pyrimidine114999913
tetrasodium    I-Pyrimidine114999913
(    O
USAN    O
)    O

:    O
2-Amino-5-formylamino-6-(5-phospho-D-ribosylamino)pyrimidin-4(3H)-one    B-Pyrimidine114999913
+    O
H2O    O
2,5-diamino-6-(5-phospho-D-ribosylamino)pyrimidin-4(3H)-one    B-Pyrimidine114999913
+    O
formate    O

:    O
J01ED02    O
Sulfalene    B-Pyrimidine114999913

5-Hydroxymethylcytosine    B-Pyrimidine114999913

5-Hydroxymethylcytosine    B-Pyrimidine114999913

AP26113    B-Pyrimidine114999913
(    O
Ariad    O
Pharmaceuticals    O
)    O

Radotinib    B-Pyrimidine114999913
(    O
INN    O
;    O
trade    O
name    O
Supect    B-Pyrimidine114999913
)    O
,    O
and    O
sometimes    O
referred    O
to    O
by    O
its    O
investigational    O
name    O
IY5511    B-Pyrimidine114999913
,    O
is    O
a    O
drug    O
for    O
the    O
treatment    O
of    O
different    O
types    O
of    O
cancer    O
,    O
most    O
notably    O
Philadelphia    O
chromosome    O
-    O
positive    O
(    O
Ph+    O
)    O
chronic    O
myeloid    O
leukemia    O
(    O
CML    O
)    O
with    O
resistance    O
or    O
intolerance    O
of    O
other    O
Bcr    O
-    O
Abl    O
tyrosine    O
-    O
kinase    O
inhibitors    O
,    O
such    O
as    O
patients    O
resistant    O
or    O
intolerant    O
to    O
imatinib    O
.    O

4,5-Diaminopyrimidine    B-Pyrimidine114999913

TB11Cs2H1    O
is    O
a    O
member    O
of    O
the    O
H    O
/    O
ACA    O
-    O
like    O
class    O
of    O
non    O
-    O
coding    O
RNA    O
(    O
ncRNA    O
)    O
molecules    O
that    O
guide    O
the    O
sites    O
of    O
modification    O
of    O
uridine    B-Pyrimidine114999913
to    O
pseudouridine    B-Pyrimidine114999913
of    O
substrate    O
RNAs    O
.    O

tRNAs    O
with    O
anticodons    O
that    O
start    O
with    O
a    O
uridine    B-Pyrimidine114999913
and    O
carrying    O
an    O
already    O
-    O
prenylated    O
adenosine    O
adjacent    O
to    O
the    O
anticodon    O
release    O
on    O
degradation    O
the    O
adenosine    O
as    O
a    O
cytokinin    O
.    O

Originally    O
based    O
on    O
observed    O
nano    O
-    O
scale    O
structures    O
in    O
geological    O
formations    O
(    O
including    O
one    O
meteorite    O
)    O
,    O
the    O
status    O
of    O
nanobacteria    O
has    O
been    O
controversial    O
,    O
with    O
some    O
researchers    O
suggesting    O
they    O
are    O
a    O
new    O
class    O
of    O
living    O
organism    O
capable    O
of    O
incorporating    O
radiolabeled    O
uridine    B-Pyrimidine114999913
,    O
and    O
others    O
attributing    O
to    O
them    O
a    O
simpler    O
,    O
abiotic    O
nature    O
.    O

It    O
is    O
an    O
ester    O
of    O
pyrophosphoric    O
acid    O
with    O
the    O
nucleoside    O
uridine    B-Pyrimidine114999913
.    O

The    O
treatment    O
essentially    O
converts    O
a    O
cytosine    O
to    O
a    O
uridine    B-Pyrimidine114999913
,    O
but    O
methylated    O
cytosines    O
would    O
be    O
unchanged    O
by    O
the    O
treatment    O
.    O

TB10Cs1H1    O
is    O
a    O
member    O
of    O
the    O
H    O
/    O
ACA    O
-    O
like    O
class    O
of    O
non    O
-    O
coding    O
RNA    O
(    O
ncRNA    O
)    O
molecule    O
that    O
guide    O
the    O
sites    O
of    O
modification    O
of    O
uridine    B-Pyrimidine114999913
to    O
pseudouridine    B-Pyrimidine114999913
of    O
substrate    O
RNAs    O
.    O

psi-    O
Ψ    O
or    O
the    O
letter    O
Q    O
)    O
is    O
an    O
isomer    O
of    O
the    O
nucleoside    O
uridine    B-Pyrimidine114999913
in    O
which    O
the    O
uracil    O
is    O
attached    O
via    O
a    O
carbon    O
-    O
carbon    O
instead    O
of    O
a    O
nitrogen    O
-    O
carbon    O
glycosidic    O
bond    O
.    O

The    O
relevant    O
nature    O
of    O
dyskerin    O
throughout    O
most    O
species    O
is    O
to    O
catalyze    O
the    O
post    O
-    O
transcriptional    O
pseudouridylation    B-Pyrimidine114999913
of    O
specific    O
uridine    B-Pyrimidine114999913
found    O
in    O
non    O
-    O
coding    O
RNAs    O
,    O
such    O
as    O
ribosomal    O
RNA    O
(    O
rRNA    O
)    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
containing    O
uridine    B-Pyrimidine114999913
at    O
position    O
54    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
and    O
tRNA    O
containing    O
ribothymidine    B-Pyrimidine114999913
at    O
position    O
54    O
.    O

Herein    O
lies    O
the    O
only    O
known    O
function    O
of    O
the    O
minicircles    O
-    O
producing    O
guide    O
RNA    O
(    O
gRNA    O
)    O
to    O
decode    O
this    O
encrypted    O
maxicircle    O
information    O
,    O
typically    O
through    O
the    O
insertion    O
or    O
deletion    O
of    O
uridine    B-Pyrimidine114999913
residues    O
.    O

Pyrimidine    B-Pyrimidine114999913
analogue    I-Pyrimidine114999913
of    O
uridine    B-Pyrimidine114999913
:    O
Idoxuridine    O
,    O
Trifluridine    B-Pyrimidine114999913

The    O
RNA    O
component    O
of    O
the    O
small    O
nuclear    O
ribonucleic    O
protein    O
or    O
snRNP    O
(    O
pronounced    O
"    O
snurp    O
"    O
)    O
is    O
rich    O
in    O
uridine    B-Pyrimidine114999913
(    O
the    O
nucleoside    O
analog    O
of    O
the    O
uracil    O
nucleotide    O
)    O
.    O

CMCT    O
like    O
DMS    O
serves    O
to    O
modify    O
the    O
exposed    O
bases    O
of    O
specific    O
nucleotides    O
,    O
which    O
are    O
uridine    B-Pyrimidine114999913
,    O
and    O
to    O
a    O
smaller    O
extent    O
guanine    O
.    O

Loss    O
of    O
ODCase    O
activity    O
leads    O
to    O
a    O
lack    O
of    O
cell    O
growth    O
unless    O
uracil    O
or    O
uridine    B-Pyrimidine114999913
is    O
added    O
to    O
the    O
media    O
.    O

#    O
The    O
T    O
arm    O
is    O
a    O
4-    O
to    O
5-    O
bp    O
stem    O
containing    O
the    O
sequence    O
TΨC    O
where    O
Ψ    O
is    O
pseudouridine    B-Pyrimidine114999913
,    O
a    O
modified    O
uridine    B-Pyrimidine114999913
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
uridine    B-Pyrimidine114999913
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
UMP    B-Pyrimidine114999913
.    O

The    O
80    O
nucleotide    O
tRNA    O
was    O
sequenced    O
by    O
first    O
being    O
digested    O
with    O
Pancreatic    O
ribonuclease    O
(    O
producing    O
fragments    O
ending    O
in    O
Cytosine    O
or    O
Uridine    B-Pyrimidine114999913
)    O
and    O
then    O
with    O
takadiastase    O
ribonuclease    O
Tl    O
(    O
producing    O
fragments    O
which    O
finished    O
with    O
Guanosine    O
)    O
.    O
Chromatography    O
and    O
identification    O
of    O
the    O
5    O
'    O
and    O
3    O
'    O
ends    O
then    O
helped    O
arrange    O
the    O
fragments    O
to    O
establish    O
the    O
RNA    O
sequence    O
.    O

Dihydrouridine    B-Pyrimidine114999913
(    O
abbreviated    O
as    O
D    B-Pyrimidine114999913
,    O
DHU    B-Pyrimidine114999913
,    O
or    O
UH2    B-Pyrimidine114999913
)    O
is    O
a    O
pyrimidine    O
nucleoside    O
which    O
is    O
the    O
result    O
of    O
adding    O
two    O
hydrogen    O
atoms    O
to    O
a    O
uridine    B-Pyrimidine114999913
,    O
making    O
it    O
a    O
fully    O
saturated    O
pyrimidine    O
ring    O
with    O
no    O
remaining    O
double    O
bonds    O
.    O

They    O
are    O
named    O
'    O
FourU    O
'    O
due    O
to    O
the    O
four    O
highly    O
conserved    O
uridine    B-Pyrimidine114999913
nucleotides    O
found    O
directly    O
opposite    O
the    O
Shine    O
-    O
Dalgarno    O
sequence    O
on    O
hairpin    O
II    O
(    O
"    O
pictured    O
"    O
)    O
.    O

5-Bromouridine    O
(    O
abbreviated    O
BrUrd    O
,    O
5BrU    O
,    O
br5Urd    O
or    O
rarely    O
the    O
one    O
letter    O
code    O
B    O
)    O
is    O
a    O
uridine    B-Pyrimidine114999913
derivative    O
with    O
a    O
bromo    O
substituent    O
at    O
the    O
fifth    O
carbon    O
.    O

Among    O
that    O
group    O
of    O
drugs    O
are    O
the    O
barbiturates    O
amobarbital    O
,    O
butalbital    O
,    O
cyclobarbital    B-Pyrimidine114999913
,    O
and    O
pentobarbital    O
.    O

Cyclobarbital    B-Pyrimidine114999913
,    O

Ocinaplon    B-Pyrimidine114999913
for    O
anxiety    O
disorders    O
.    O

Quinelorane    B-Pyrimidine114999913
–    O
affinity    O
for    O
D2    O
>    O
D3    O

1-(2-Pyrimidinyl)piperazine    B-Pyrimidine114999913
(    O
1-PP    B-Pyrimidine114999913
,    O
1-PmP    B-Pyrimidine114999913
)    O
is    O
a    O
chemical    O
compound    O
and    O
piperazine    O
derivative    O
.    O

However    O
,    O
similarly    O
to    O
buspirone    O
,    O
gepirone    O
metabolizes    O
into    O
1-(2-pyrimidinyl)piperazine    B-Pyrimidine114999913
,    O
which    O
is    O
known    O
to    O
act    O
as    O
a    O
potent    O
antagonist    O
of    O
the    O
α2-adrenergic    O
receptor    O
.    O

Pyrantel    B-Pyrimidine114999913

Mebendazole    O
,    O
Pyrantel    B-Pyrimidine114999913
Pamoate    I-Pyrimidine114999913

Pyrantel    B-Pyrimidine114999913
pamoate    I-Pyrimidine114999913
is    O
also    O
used    O
,    O
and    O
a    O
closely    O
related    O
variant    O
,    O
pyrantel    O
tartrate    O
,    O
can    O
be    O
fed    O
as    O
a    O
daily    O
dose    O
that    O
is    O
effective    O
at    O
killing    O
larvae    O
.    O

Other    O
anthelmintics    O
that    O
can    O
be    O
used    O
include    O
thiabendazole    O
,    O
mebendazole    O
,    O
levamisole    O
and    O
pyrantel    B-Pyrimidine114999913
pamoate    I-Pyrimidine114999913
.    O

Pyrantel    B-Pyrimidine114999913
pamoate    I-Pyrimidine114999913
(    O
for    O
most    O
nematode    O
infections    O
)    O

File    O
:    O
Nimustine    B-Pyrimidine114999913

Alfuzosin    B-Pyrimidine114999913
(    O
used    O
in    O
benign    O
prostatic    O
hyperplasia    O
)    O

alfuzosin    B-Pyrimidine114999913
for    O
retention    O
,    O

Exercise    O
or    O
dipyridamole    B-Pyrimidine114999913
induces    O
widening    O
(    O
vasodilation    O
)    O
of    O
normal    O
coronary    O
arteries    O
.    O

Dipyridamole    B-Pyrimidine114999913
antagonizes    O
this    O
receptor    O
too    O
,    O
but    O
has    O
various    O
other    O
mechanisms    O
of    O
antiplatelet    O
activity    O
as    O
well    O
.    O

Vasodilators    O
acting    O
as    O
adenosine    O
receptor    O
agonists    O
,    O
such    O
as    O
adenosine    O
itself    O
,    O
and    O
dipyridamole    B-Pyrimidine114999913
(    O
brand    O
name    O
"    O
Persantine    O
"    O
)    O
,    O
which    O
acts    O
indirectly    O
at    O
the    O
receptor    O
.    O

Following    O
this    O
,    O
myocardial    O
stress    O
is    O
induced    O
,    O
either    O
by    O
exercise    O
or    O
pharmacologically    O
with    O
adenosine    O
,    O
dobutamine    O
or    O
dipyridamole    B-Pyrimidine114999913
)    O
,    O
which    O
increase    O
the    O
heart    O
rate    O
or    O
by    O
regadenoson(Lexiscan    O
)    O
,    O
a    O
vasodilator    O
.    O

Dipyridamole    B-Pyrimidine114999913
(    O
trademarked    O
as    O
Persantine    B-Pyrimidine114999913
and    O
others    O
)    O
is    O
a    O
medication    O
that    O
inhibits    O
blood    O
clot    O
formation    O
when    O
given    O
chronically    O
and    O
causes    O
blood    O
vessel    O
dilation    O
when    O
given    O
at    O
high    O
doses    O
over    O
a    O
short    O
time    O
.    O

Thiotetrabarbital    B-Pyrimidine114999913
(    O
INN    O
;    O
Thionarcex    B-Pyrimidine114999913
)    O
is    O
a    O
drug    O
which    O
is    O
a    O
short    O
-    O
acting    O
barbiturate    O
derivative    O
that    O
is    O
used    O
as    O
an    O
anesthetic    O
.    O

Urapidil    B-Pyrimidine114999913

amprolium    B-Pyrimidine114999913

Amprolium    B-Pyrimidine114999913
(    O
INN    O
,    O
trade    O
names    O
Amprovine    B-Pyrimidine114999913
,    O
Amprolium    B-Pyrimidine114999913
,    O
Amprol    B-Pyrimidine114999913
,    O
Anticoccid    B-Pyrimidine114999913
)    O
is    O
a    O
coccidiostat    O
used    O
in    O
poultry    O
.    O

:    O
N03AA04    O
Barbexaclone    B-Pyrimidine114999913

Iclaprim    B-Pyrimidine114999913

Lesopitron    B-Pyrimidine114999913

Proxibarbital    B-Pyrimidine114999913
(    O
Ipronal    O
)    O
is    O
a    O
barbiturate    O
derivative    O
synthesized    O
in    O
1956    O
.    O

D    O
is    O
found    O
in    O
tRNA    O
and    O
rRNA    O
molecules    O
as    O
a    O
nucleoside    O
;    O
the    O
corresponding    O
nucleobase    O
is    O
5,6-dihydrouracil    B-Pyrimidine114999913
.    O

Phostebupirim    B-Pyrimidine114999913

Thymidylate    O
synthetase    O
is    O
an    O
enzyme    O
that    O
catalyzes    O
the    O
conversion    O
of    O
deoxyuridine    B-Pyrimidine114999913
monophosphate    I-Pyrimidine114999913
(    O
dUMP    O
)    O
to    O
deoxythymidine    B-Pyrimidine114999913
monophosphate    I-Pyrimidine114999913
(    O
dTMP    O
)    O
.    O

With    O
inhibition    O
of    O
TS    O
,    O
an    O
imbalance    O
of    O
deoxynucleotides    O
and    O
increased    O
levels    O
of    O
dUMP    B-Pyrimidine114999913
arise    O
.    O

By    O
means    O
of    O
reductive    O
methylation    O
,    O
deoxyuridine    B-Pyrimidine114999913
monophosphate    I-Pyrimidine114999913
(    O
dUMP    O
)    O
and    O
N5,N10-methylene    O
tetrahydrofolate    O
are    O
together    O
used    O
to    O
form    O
dTMP    O
,    O
yielding    O
dihydrofolate    O
as    O
a    O
secondary    O
product    O
.    O

It    O
is    O
also    O
a    O
metabolite    O
of    O
capecitabine    B-Pyrimidine114999913
.    O

Benznidazole    O
and    O
other    O
nitroimidazoles    O
have    O
been    O
shown    O
to    O
decrease    O
the    O
rate    O
of    O
clearance    O
of    O
5-fluorouracil    O
(    O
including    O
5-fluorouracil    O
produced    O
from    O
its    O
prodrugs    O
capecitabine    B-Pyrimidine114999913
,    O
doxifluridine    O
,    O
and    O
tegafur    O
)    O
.    O

The    O
anti    O
-    O
cancer    O
medication    O
capecitabine    B-Pyrimidine114999913
may    O
cause    O
the    O
loss    O
of    O
fingerprints    O
.    O

Chemotherapy    O
commonly    O
used    O
is    O
similar    O
to    O
other    O
squamous    O
cell    O
epithelial    O
neoplasms    O
,    O
such    O
as    O
platinum    O
analogues    O
,    O
anthracyclines    O
such    O
as    O
doxorubicin    O
,    O
and    O
antimetabolites    O
such    O
as    O
5-FU    O
and    O
capecitabine    B-Pyrimidine114999913
.    O

Important    O
role    O
(    O
David    O
Cameron    O
as    O
joint    O
global    O
Chief    O
Investigator    O
)    O
in    O
the    O
pivotal    O
clinical    O
trial    O
that    O
tested    O
the    O
hypothesis    O
that    O
the    O
combination    O
of    O
lapatinib    B-Pyrimidine114999913
and    O
the    O
cytotoxic    O
drug    O
capecitabine    B-Pyrimidine114999913
would    O
be    O
superior    O
to    O
capecitabine    O
alone    O
in    O
patients    O
with    O
HER2    O
+    O
metastatic    O
breast    O
cancer    O
that    O
had    O
progressed    O
despite    O
trastuzumab    O
treatment    O
.    O

Chemotherapy    O
is    O
usually    O
delivered    O
intravenously    O
,    O
although    O
a    O
number    O
of    O
agents    O
can    O
be    O
administered    O
orally    O
(    O
e.g.    O
specialty    O
drugs    O
,    O
melphalan    O
(    O
trade    O
name    O
Alkeran    O
)    O
,    O
busulfan    O
,    O
capecitabine    B-Pyrimidine114999913
)    O
.    O

Pyrimethanil    B-Pyrimidine114999913
is    O
a    O
broad    O
spectrum    O
fungicide    O
often    O
applied    O
to    O
seeds    O
.    O

cytarabine    B-Pyrimidine114999913

Cytarabine    B-Pyrimidine114999913

These    O
compounds    O
led    O
to    O
the    O
synthesis    O
of    O
a    O
new    O
generation    O
,    O
sugar    O
modified    O
nucleoside    O
analog    O
vidarabine    O
,    O
and    O
the    O
related    O
compound    O
cytarabine    B-Pyrimidine114999913
.    O

Pyrimidine    O
antagonists    O
(    O
cytarabine    B-Pyrimidine114999913
)    O

File    O
:    O
Cytarabine    B-Pyrimidine114999913

Additionally    O
,    O
omigapil    O
can    O
prevent    O
NMDA    O
and    O
kainate    O
receptor    O
excitotoxicity    O
in    O
rat    O
cortical    O
neurons    O
as    O
well    O
as    O
toxicity    O
from    O
cytosine    B-Pyrimidine114999913
arabinoside    I-Pyrimidine114999913
(    O
ara    O
C    O
)    O
in    O
cerebellar    O
granule    O
cells    O
.    O

The    O
patient    O
was    O
prescribed    O
six    O
oral    O
drugs    O
,    O
intrathecal    O
cytarabine    B-Pyrimidine114999913
and    O
intravenous    O
vincristine    O
by    O
another    O
doctor    O
,    O
and    O
was    O
injected    O
by    O
the    O
trainee    O
later    O
the    O
day    O
.    O

Cytarabine    B-Pyrimidine114999913
,    O
a    O
DNA    O
-    O
synthesis    O
inhibitor    O
also    O
known    O
as    O
ara    O
-    O
C    O
,    O
is    O
cited    O
as    O
the    O
classic    O
cell    O
cycle    O
phase    O
-    O
specific    O
agent    O
.    O

Phleomycin    B-Pyrimidine114999913
D1    I-Pyrimidine114999913
(    O
zeocin    O
)    O

Other    O
agents    O
that    O
have    O
been    O
proposed    O
to    O
target    O
polyomavirus    O
BK    O
,    O
such    O
as    O
cidofovir    B-Pyrimidine114999913
,    O
fluoroquinolones    O
,    O
leflunomide    O
,    O
and    O
statins    O
are    O
far    O
from    O
established    O
and    O
the    O
published    O
results    O
on    O
their    O
effectivity    O
are    O
conflicting    O
.    O

There    O
are    O
no    O
specific    O
antiviral    O
drugs    O
in    O
common    O
use    O
at    O
this    O
time    O
for    O
FVR    O
,    O
although    O
one    O
study    O
has    O
shown    O
that    O
ganciclovir    O
,    O
PMEDAP    O
,    O
and    O
cidofovir    B-Pyrimidine114999913
hold    O
promise    O
for    O
treatment    O
.    O

In    O
June    O
1996    O
,    O
Gilead    O
launched    O
Vistide    O
(    O
cidofovir    B-Pyrimidine114999913
injection    O
)    O
for    O
the    O
treatment    O
of    O
cytomegalovirus    O
(    O
CMV    O
)    O
retinitis    O
in    O
patients    O
with    O
AIDS    O
.    O

Acyclic    B-Pyrimidine114999913
nucleoside    I-Pyrimidine114999913
phosphonate    I-Pyrimidine114999913
,    O
a    O
group    O
of    O
antiviral    O
drugs    O
.    O

In    O
terms    O
of    O
the    O
treatment    O
of    O
cytomegalovirus    O
retinitis    O
,    O
oral    O
valganciclovir    O
,    O
intravenous    O
ganciclovir    O
,    O
IV    O
foscarnet    O
,    O
and    O
IV    O
cidofovir    B-Pyrimidine114999913
are    O
all    O
efficient    O
in    O
the    O
treatment    O
of    O
this    O
condition    O
.    O

Other    O
pyrazolopyrimidine    O
drugs    O
include    O
zaleplon    B-Pyrimidine114999913
and    O
indiplon    O
.    O

This    O
is    O
the    O
same    O
intermediate    O
as    O
was    O
used    O
in    O
the    O
synthesis    O
of    O
zaleplon    B-Pyrimidine114999913
in    O
which    O
the    O
nitrile    O
is    O
replaced    O
by    O
a    O
2-acetylpyridil    O
moiety    O
.    O

Some    O
studies    O
have    O
shown    O
that    O
zaleplon    B-Pyrimidine114999913
,    O
which    O
has    O
a    O
short    O
elimination    O
half    O
-    O
life    O
,    O
may    O
be    O
suitable    O
for    O
middle    O
-    O
of    O
-    O
the    O
-    O
night    O
administration    O
because    O
it    O
does    O
not    O
impair    O
next    O
day    O
performance    O
.    O

zaleplon    B-Pyrimidine114999913
(    O
depressant    O
z    O
-    O
drug    O
)    O

Zaleplon    B-Pyrimidine114999913
(    O
Sonata    O
)    O

Paliperidone    B-Pyrimidine114999913
(    O
Invega    O
)    O

Tends    O
to    O
produce    O
a    O
moderate    O
amount    O
of    O
sedation    O
,    O
less    O
than    O
clozapine    O
and    O
chlorpromazine    O
but    O
more    O
than    O
aripiprazole    O
,    O
amisulpride    O
,    O
paliperidone    B-Pyrimidine114999913
and    O
sertindole    O
and    O
approximately    O
that    O
of    O
quetiapine    O
and    O
risperidone    B-Pyrimidine114999913
.    O

It    O
tends    O
to    O
produce    O
hyperolactinaemia    O
less    O
often    O
than    O
risperidone    B-Pyrimidine114999913
,    O
paliperidone    B-Pyrimidine114999913
and    O
the    O
typical    O
antipsychotics    O
but    O
more    O
often    O
than    O
quetiapine    O
and    O
clozapine    O
.    O

Paliperidone    B-Pyrimidine114999913

Paliperidone    B-Pyrimidine114999913

Nilotinib    B-Pyrimidine114999913
is    O
a    O
phenylamino    O
-    O
pyrimidine    O
derivative    O
that    O
is    O
structurally    O
related    O
to    O
imatinib    O
.    O

Crystal    O
structure    O
of    O
Abl    O
kinase    O
domain    O
(    O
blue    O
)    O
in    O
complex    O
with    O
nilotinib    B-Pyrimidine114999913
(    O
red    O
)    O
.    O

In    O
those    O
cases    O
other    O
inhibitors    O
such    O
as    O
dasatinib    B-Pyrimidine114999913
and    O
nilotinib    B-Pyrimidine114999913
can    O
be    O
used    O
.    O

Next    O
,    O
aspartate    O
carbamoyltransferase    O
catalyzes    O
a    O
condensation    O
reaction    O
between    O
aspartate    O
and    O
carbamoyl    O
phosphate    O
to    O
form    O
carbamoyl    O
aspartic    O
acid    O
,    O
which    O
is    O
cyclized    O
into    O
4,5-dihydroorotic    B-Pyrimidine114999913
acid    I-Pyrimidine114999913
by    O
dihydroorotase    O
.    O

4,5-Dihydroorotic    B-Pyrimidine114999913
acid    I-Pyrimidine114999913

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Pyrimidine114999913
and    O
sn    O
-    O
glycerol    O
3-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CDP    O
-    O
glycerol    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Pyrimidine114999913
and    O
N    O
-    O
acylneuraminate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CMP    O
-    O
N    O
-    O
acylneuraminate    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
CTP    B-Pyrimidine114999913
and    O
N    O
-    O
methylethanolamine    O
phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
CDP    O
-    O
N    O
-    O
methylethanolamine    O
.    O

Phosphatidate    O
cytidylyltransferase    O
(    O
also    O
known    O
as    O
CDP-    O
diacylglycerol    O
synthase    O
)    O
(    O
CDS    O
)    O
is    O
the    O
enzyme    O
that    O
catalyzes    O
the    O
synthesis    O
of    O
CDP    O
-    O
diacylglycerol    O
from    O
cytidine    B-Pyrimidine114999913
triphosphate    I-Pyrimidine114999913
and    O
phosphatidate    O
.    O

However    O
,    O
archaeal    O
riboflavin    O
kinases    O
in    O
general    O
utilize    O
CTP    B-Pyrimidine114999913
rather    O
than    O
ATP    O
as    O
the    O
donor    O
nucleotide    O
,    O
catalyzing    O
the    O
reaction    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
ATP    O
and    O
thiamine    O
diphosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
ADP    O
and    O
thiamine    B-Pyrimidine114999913
triphosphate    I-Pyrimidine114999913
.    O

nifekalant    B-Pyrimidine114999913
(    O
INN    O
)    O

Employing    O
intravascular    O
ultrasound    O
(    O
IVUS    O
)    O
,    O
they    O
showed    O
regression    O
of    O
the    O
atherosclerotic    O
plaques    O
in    O
response    O
to    O
a    O
high    O
dose    O
of    O
rosuvastatin    B-Pyrimidine114999913

Also    O
,    O
co    O
-    O
administration    O
of    O
eluxadoline    O
with    O
rosuvastatin    B-Pyrimidine114999913
may    O
increase    O
the    O
risk    O
of    O
rhabdomyolysis    O
.    O

The    O
AURORA    O
trial    O
(    O
A    O
Study    O
to    O
Evaluate    O
the    O
Use    O
of    O
Rosuvastatin    B-Pyrimidine114999913
in    O
Subjects    O
on    O
Regular    O
Hemodialysis    O
:    O
An    O
Assessment    O
of    O
Survival    O
and    O
Cardiovascular    O
Events    O
)    O
was    O
a    O
randomized    O
,    O
double    O
-    O
blind    O
,    O
placebo    O
-    O
controlled    O
study    O
investigating    O
the    O
use    O
of    O
rosuvastatin    B-Pyrimidine114999913
in    O
the    O
prevention    O
of    O
cardiovascular    O
disease    O
among    O
patients    O
undergoing    O
chronic    O
hemodialysis    O
.    O

The    O
trial    O
was    O
sponsored    O
,    O
in    O
part    O
,    O
by    O
AstraZeneca    O
,    O
the    O
marketer    O
of    O
Crestor    B-Pyrimidine114999913
.    O

Aditoprim    B-Pyrimidine114999913
is    O
an    O
antibacterial    O
dihydrofolate    O
reductase    O
inhibitor    O
.    O

Etravirine    O
is    O
a    O
diarylpyrimidine    B-Pyrimidine114999913
(    O
DAPY    O
)    O
,    O
a    O
type    O
of    O
organic    O
molecule    O
with    O
some    O
conformational    O
isomerism    O
that    O
can    O
bind    O
the    O
enzyme    O
reverse    O
transcriptase    O
in    O
multiple    O
conformations    O
,    O
allowing    O
for    O
a    O
more    O
robust    O
interaction    O
between    O
etravirine    O
and    O
the    O
enzyme    O
,    O
even    O
in    O
the    O
presence    O
of    O
mutations    O
.    O

Adenosine    B-Pyrimidine114999913
thiamine    I-Pyrimidine114999913
triphosphate    I-Pyrimidine114999913
(    O
AThTP    O
)    O
or    O
thiaminylated    O
adenosine    O
triphosphate    O
has    O
recently    O
been    O
discovered    O
in    O
"    O
Escherichia    O
coli    O
"    O
,    O
where    O
it    O
accumulates    O
as    O
a    O
result    O
of    O
carbon    O
starvation    O
.    O

Idoxuridine    O
and    O
Trifluridine    B-Pyrimidine114999913
are    O
variants    O
of    O
deoxyuridine    O
used    O
as    O
antiviral    O
drugs    O
.    O

Pyrimidine    B-Pyrimidine114999913
analogue    I-Pyrimidine114999913
of    O
uridine    B-Pyrimidine114999913
:    O
Idoxuridine    O
,    O
Trifluridine    B-Pyrimidine114999913

Trifluridine    B-Pyrimidine114999913
,    O
a    O
antiviral    O
and    O
anticancer    O
medication    O

Early    O
pesticide    O
development    O
included    O
Gramoxone    O
(    O
1962    O
,    O
a    O
herbicide    O
)    O
,    O
the    O
insecticides    O
pirimiphos-methyl    B-Pyrimidine114999913
in    O
1967    O
and    O
pirimicarb    B-Pyrimidine114999913
in    O
1970    O
,    O
brodifacoum    O
(    O
a    O
rodenticide    O
)    O
was    O
developed    O
in    O
1974    O
;    O
in    O
the    O
late    O
1970s    O
,    O
ICI    O
was    O
involved    O
in    O
the    O
early    O
development    O
of    O
synthetic    O
pyrethroid    O
insecticides    O
such    O
as    O
lambda    O
-    O
cyhalothrin    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
S    O
-    O
adenosyl    O
methionine    O
and    O
tRNA    O
containing    O
uridine    B-Pyrimidine114999913
at    O
position    O
54    O
,    O
whereas    O
its    O
two    O
products    O
are    O
S    O
-    O
adenosylhomocysteine    O
and    O
tRNA    O
containing    O
ribothymidine    B-Pyrimidine114999913
at    O
position    O
54    O
.    O

Tegafur/uracil    B-Pyrimidine114999913
,    O
a    O
chemotherapy    O
drug    O
used    O
in    O
the    O
treatment    O
of    O
cancer    O

Mizolastine    B-Pyrimidine114999913

Drugs    O
of    O
the    O
5-nitro    O
variety    O
include    O
metronidazole    O
,    O
tinidazole    O
,    O
nimorazole    O
,    O
dimetridazole    O
,    O
6-Amino    O
PA824    O
,    O
ornidazole    O
,    O
megazol    O
,    O
and    O
azanidazole    B-Pyrimidine114999913
.    O

Aprobarbital    B-Pyrimidine114999913

,    O
the    O
sGC    O
activators    O
cinaciguat    O
and    O
riociguat    B-Pyrimidine114999913
were    O
undergoing    O
clinical    O
trials    O
for    O
the    O
treatment    O
of    O
PAH    O
.    O

Kopexil    B-Pyrimidine114999913
(    O
INCI    O
name    O
diaminopyrimidine    B-Pyrimidine114999913
oxide    I-Pyrimidine114999913
,    O
trade    O
name    O
Aminexil    B-Pyrimidine114999913
)    O
is    O
a    O
chemical    O
compound    O
similar    O
to    O
minoxidil    O
.    O

In    O
-    O
feed    O
pyrimethamine    O
and    O
sulfadimethoxine    B-Pyrimidine114999913
can    O
help    O
prevent    O
the    O
disease    O
.    O

It    O
is    O
a    O
building    O
block    O
for    O
many    O
drugs    O
,    O
including    O
dextromethorphan    O
,    O
amiloride    O
,    O
sulfadimethoxine    B-Pyrimidine114999913
,    O
and    O
allopurinol    O
,    O
and    O
also    O
for    O
Peldesine    O
.    O

Eukaryotic    O
cells    O
also    O
contain    O
5-methylcytosine    B-Pyrimidine114999913
,    O
thought    O
to    O
be    O
involved    O
in    O
the    O
control    O
of    O
gene    O
transcription    O
,    O
which    O
can    O
become    O
deaminated    O
into    O
thymine    O
.    O

Examples    O
include    O
C    O
→    O
U    O
and    O
A    O
→    O
HX    O
(    O
hypoxanthine    O
)    O
,    O
which    O
can    O
be    O
corrected    O
by    O
DNA    O
repair    O
mechanisms    O
;    O
and    O
5MeC    O
(    O
5-methylcytosine    B-Pyrimidine114999913
)    O
→    O
T    O
,    O
which    O
is    O
less    O
likely    O
to    O
be    O
detected    O
as    O
a    O
mutation    O
because    O
thymine    O
is    O
a    O
normal    O
DNA    O
base    O
.    O

Treatment    O
of    O
DNA    O
with    O
bisulfite    O
converts    O
cytosine    O
residues    O
to    O
uracil    O
,    O
but    O
leaves    O
5-methylcytosine    B-Pyrimidine114999913
residues    O
unaffected    O
.    O

Instead    O
,    O
primer    O
pairs    O
are    O
designed    O
themselves    O
to    O
be    O
"    O
methylated    O
-    O
specific    O
"    O
by    O
including    O
sequences    O
complementing    O
only    O
unconverted    O
5-methylcytosine    B-Pyrimidine114999913
,    O
or    O
,    O
on    O
the    O
converse    O
,    O
"    O
unmethylated    O
-    O
specific    O
"    O
,    O
complementing    O
thymines    O
converted    O
from    O
unmethylated    O
cytosines    O
.    O

Such    O
primers    O
will    O
anneal    O
only    O
to    O
sequences    O
that    O
are    O
methylated    O
,    O
and    O
thus    O
containing    O
5-methylcytosine    B-Pyrimidine114999913
that    O
are    O
resistant    O
to    O
conversion    O
by    O
bisulfite    O
.    O

5-Methylcytosine    B-Pyrimidine114999913

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Pyrimidine114999913
and    O
RNAn    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
RNAn+1    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Pyrimidine114999913
and[N    O
-    O
acetyl    O
-    O
alpha    O
-    O
D    O
-    O
glucosamine    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP    O
-    O
N    O
-    O
acetyl    O
-    O
D    O
-    O
glucosamine    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Pyrimidine114999913
and    O
alpha    O
-    O
D    O
-    O
galactose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP    O
-    O
galactose    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Pyrimidine114999913
and    O
monosaccharide    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP    O
-    O
monosaccharide    O
.    O

Thus    O
,    O
the    O
two    O
substrates    O
of    O
this    O
enzyme    O
are    O
UTP    B-Pyrimidine114999913
and    O
alpha    O
-    O
D    O
-    O
xylose    O
1-phosphate    O
,    O
whereas    O
its    O
two    O
products    O
are    O
diphosphate    O
and    O
UDP    O
-    O
xylose    O
.    O

Tocilizumab    O
was    O
first    O
used    O
in    O
large    O
-    O
cell    O
lung    O
carcinoma    O
;    O
in    O
phase    O
I    O
/    O
II    O
trial    O
of    O
tocilizumab    O
in    O
ovarian    O
cancer    O
EGFR    O
pathway    O
upregulation    O
was    O
observed    O
and    O
after    O
inhibition    O
of    O
this    O
pathway    O
by    O
gefitinib    B-Pyrimidine114999913
tumor    O
growth    O
was    O
decreased    O
both    O
"    O
in    O
vitro    O
"    O
and    O
"    O
in    O
vivo    O
"    O
.    O

Gefitinib    B-Pyrimidine114999913
(    O
Iressa    O
,    O
also    O
known    O
as    O
ZD1839    O
)    O
,    O
targets    O
the    O
epidermal    O
growth    O
factor    O
receptor    O
(    O
EGFR    O
)    O
tyrosine    O
kinase    O
and    O
is    O
approved    O
in    O
the    O
U.S.    O
for    O
non    O
small    O
cell    O
lung    O
cancer    O
.    O

Drugs    O
such    O
as    O
panitumumab    O
,    O
cetuximab    O
,    O
gefitinib    B-Pyrimidine114999913
,    O
erlotinib    B-Pyrimidine114999913
,    O
afatinib    O
,    O
and    O
lapatinib    O
are    O
used    O
to    O
inhibit    O
it    O
.    O

Gefitinib    B-Pyrimidine114999913
(    O
ZD1839    B-Pyrimidine114999913
)    O
(    O
INN    O
,    O
,    O
trade    O
name    O
Iressa    B-Pyrimidine114999913
)    O
is    O
a    O
drug    O
used    O
for    O
certain    O
breast    O
,    O
lung    O
and    O
other    O
cancers    O
.    O

In    O
phase    O
I    O
/    O
II    O
trial    O
of    O
tocilizumab    O
in    O
ovarian    O
cancer    O
EGFR    O
pathway    O
upregulation    O
was    O
observed    O
and    O
after    O
inhibition    O
of    O
this    O
pathway    O
by    O
gefitinib    B-Pyrimidine114999913
tumor    O
growth    O
was    O
decreased    O
both    O
"    O
in    O
vitro    O
"    O
and    O
"    O
in    O
vivo    O
"    O
.    O

In    O
2003    O
,    O
he    O
recognized    O
that    O
certain    O
patients    O
with    O
lung    O
cancer    O
responded    O
well    O
to    O
the    O
drug    O
Iressa    B-Pyrimidine114999913
where    O
few    O
other    O
patients    O
showed    O
effect    O
.    O
Sequencing    O
the    O
patient    O
's    O
cancers    O
,    O
they    O
identified    O
specific    O
mutation    O
in    O
epidermal    O
growth    O
factor    O
receptor    O
(    O
EGFR    O
)    O
that    O
resulted    O
in    O
sensitivity    O
to    O
certain    O
drugs    O
.    O

Fursultiamine    B-Pyrimidine114999913
(    O
INN    O
;    O
Adventan    B-Pyrimidine114999913
,    O
Alinamin-F    B-Pyrimidine114999913
,    O
Benlipoid    B-Pyrimidine114999913
,    O
Bevitol    B-Pyrimidine114999913
Lipophil    I-Pyrimidine114999913
,    O
Judolor    B-Pyrimidine114999913
,    O
Lipothiamine    B-Pyrimidine114999913
)    O
,    O
chemically    O
thiamine    B-Pyrimidine114999913
tetrahydrofurfuryl    I-Pyrimidine114999913
disulfide    I-Pyrimidine114999913
(    O
TTFD    B-Pyrimidine114999913
)    O
,    O
is    O
a    O
disulfide    O
derivative    O
of    O
thiamine    O
,    O
or    O
an    O
allithiamine    B-Pyrimidine114999913
.    O


